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 One of the many unsolved mysteries in neuroscience is why the peripheral 
nervous system can extensively regenerate its axons while the central nervous system is 
limited. Despite its capacity for regeneration, peripheral nerve regeneration is often 
unsatisfactory and slow, leading to limited functional recovery following traumatic nerve 
injuries or in response to motor neuron disease and peripheral neuropathies. In an attempt 
to identify mechanisms and targets for drugs, researchers have discovered many different 
regulators of peripheral nerve regeneration. Despite this intense interest in understanding 
how peripheral nerves regenerate, there are still no approved therapeutics for enhancing 
peripheral nerve regeneration. This thesis identifies BACE1 as a novel regulator of 
peripheral nerve regeneration and inhibitors of BACE1 as potential therapeutics. Previous 
research done in our lab demonstrated that BACE1 KO mice have enhanced peripheral 
nerve regeneration following a sciatic nerve crush injury. We then hypothesized that 
BACE1 activity levels have an inverse relationship with axonal regeneration. This thesis 
investigated this hypothesis using mice which overexpress BACE1 in their neurons and 
demonstrated impaired regeneration following a sciatic nerve crush injury. We then 
determined whether BACE1 inhibitors could be utilized as a potential therapy for 
enhancing peripheral nerve regeneration, both in terms of traumatic nerve injury as well 
as a peripheral neurodegenerative disease. BACE1 inhibitors were administered to WT 
mice after performing either a sciatic nerve crush or a partial nerve transection of the 
lateral thoracic nerve. Mice treated with the inhibitors had improved muscle reinnervation 
and electrophysiological function following the nerve crush, and enhanced terminal 




to improve muscle innervation, electrophysiological function, and enhanced sprouting in 
the SOD1G93A mouse model of ALS. Taken together, the data outlined in this thesis 
demonstrated that BACE1 activity not only negatively regulates peripheral nerve 
regeneration, but that providing mice with BACE1 inhibitors enhance axonal 
regeneration following both traumatic nerve injuries and motor neuron disease. 
 
Mentor: Dr. Mohamed H. Farah 
Thesis committee: Dr. Lee J. Martin, Dr. Charles G. Eberhart, and Dr. Barbara S. Slusher  

















At the risk of sounding cheesy, I think that the best way to begin my 
acknowledgements is with the proverb “it takes a village to raise a child.” Going all the 
way back to kindergarten, many people have been involved in encouraging and 
mentoring me to become the scientist I am today. I never would have been able to 
accomplish all of these things without all the support of my family, friends, and mentors. 
I would first like to thank my family since none of this would have been possible 
without them. My mother and father have been my biggest supporters from day one and I 
don’t think I could ever thank them enough for all that they have sacrificed over the years 
in order for me to be here. Thank you for putting up with my hysterical phone calls after 
every exam panicking that I failed, only to later discover an A. Thank you for always 
encouraging me to strive to be the best that I could be but also supporting me when I fell 
short. Thank you for highlighting the importance of education and that the best way to 
feel successful was to make my own way in life with my own successes. I will be forever 
grateful for all the love and support given throughout my life. I would also like to thank 
my brother for also putting up with me and supporting me. I love you all so much. 
 I would next like to thank my thesis mentor, Mohamed, for all the support over 
the past 4 years. I don’t think I could have ever found a better mentor. He is always 
looking on the bright side of things, even when things were going horribly wrong. He 
taught me that there can always be a positive frame of reference to tackle a problem and 
that even unexpected setbacks can be great if you just take the time to think and learn 
from them. He always supported any ideas I had, even when those ideas were less than 




 I also want to thank former members of the Farah lab; Katelyn Russell, Aniqa 
Tasnim, Lijuan Liu, Ping Xue, Nirmal Andrapalliyal, and Ashley Lea. I especially would 
like to thank Katelyn for teaching me all the electrophysiology methodologies, without 
her expertise this body of work would be nothing. To the current members of the lab, 
John Fissel and Katie Marshall, thanks for all the laughs along the way. Katie, you kept 
my sanity in the last few months by helping me out and I will be forever grateful. May 
the science gods be favorable towards your dissertations! 
 To my thesis committee members, Lee Martin, Charles Eberhart, and Barbara 
Slusher, thank you for all the guidance given to me over the past 4 years. My thesis 
would not be the coherent body of work presented here without the critiques and 
suggestions of all of you. I have truly grown as a scientist because of what I have learned 
from the wisdom of my committee. I would like to thank Lee for agreeing to read this 
thesis. I would also like to thank Barbara for continuing to support me through my post 
doc and providing me with support as I pursue my industry career goals. 
 A big thank you to Matthew Kennedy at Merck for generously agreeing to 
provide our lab with a clinically relevant BACE1 inhibitor and following the progress of 
my project over the past couple of years. I truly appreciate all the advice given to me 
about how to best achieve my goals of transitioning over to a position in industry.  
 I would also like to thank the Pathobiology program. I still remember sitting on 
the plane on my way to my interview and thinking that I should probably just head 
straight back home. As soon as I met with the Pathobiology people, however, my fears 
completely dissipated and I have never looked back since. To the past and present 




would have gotten all the proper paper work in order and on time. To all the faculty 
members of the program, thank you for sharing your wisdom with me and helping to 
broaden my scientific mind. And lastly, to the group of students, thank you all for 
laughing and crying with me throughout these 4 years. I would take the time to give a 
shout out to each one of you individually, but that would probably add another 5 pages to 
this acknowledgement section. Just know that I cherish each and every one of you and all 
of the memories we’ve shared. You’ve made my time in the grad school truly memorable 
and if I could do it all over again I would choose the Pathobiology program every time.  
 I would also like to thank all of the teachers and professors who were instrumental 
to the lead up towards my entering graduate school. To my late grade 8 teacher Mrs. 
Chapman, you were the first teacher to truly believe in my potential and encourage me to 
push the envelope. To all my high school science teachers, thank you for instilling a love 
of science in me and sowing the seeds of scientific inquiry. I would like to thank Dr. 
Karine Auclair for giving me my first ever lab position. My time there was the catalyst 
needed to decide on pursuing a career in research over medical school. I would especially 
like to thank Kenward Vong and Aaron Larsen for taking the time to mentor me while I 
was in the lab and continuing to give me advice over the years. I would also like to thank 
Dr. Kathleen Cullen for taking me on to complete my honours thesis. Lastly, I would like 
to thank Dr. Claire Brown for teaching me all I know about microscopy. My thesis 
benefitted greatly from all the expertise I learned during my time in your lab. 
 This thesis is a testament to all of the support and encouragement of my own 





Table of Contents 
ABSTRACT II 
ACKNOWLEDGEMENTS IV 
LIST OF FIGURES XIII 
LIST OF TABLES XV 
CHAPTER 1: INTRODUCTION 1 
INTRODUCTION 1 
BETA SECRETASE AND ITS MANY SUBSTRATES 4 
BETA-SITE APP CLEAVING ENZYME 1 (BACE1) 4 
BACE1’S ROLE IN AMYLOID PRECURSOR PROTEIN PROCESSING 5 
BACE1 IMPACTS PERIPHERAL MYELINATION VIA NEUREGULIN-1 TYPE III 5 
BACE1 ACTIVITY INFLUENCES AXONAL GUIDANCE VIA MULTIPLE ADHESION MOLECULES 6 
BACE2 8 
HOW DO PERIPHERAL NERVES REGENERATE? 8 
THE TYPE AND EXTENT OF PERIPHERAL NERVE INJURY AFFECTS REGENERATION EFFICACY 8 
AXONAL SPROUTING FROM NEIGHBORING INTACT AXONS CONTRIBUTES TO REINNERVATION 11 
REGENERATION ASSOCIATED GENES 13 
MODELING PERIPHERAL NERVE INJURIES IN MICE 14 
THE SCIATIC NERVE IS A SIMPLE MODEL TO STUDY NERVE CRUSH INJURIES 14 
UTILIZING THE LATERAL THORACIC NERVE – CUTANEOUS MAXIMUS MUSCLE SYSTEM TO MODEL PARTIAL 
NERVE INJURIES 16 
EXAMPLES OF DISEASES THAT LEAD TO PERIPHERAL NERVE DEGENERATION 18 




DIABETIC PERIPHERAL NEUROPATHIES 19 
AMYOTROPHIC LATERAL SCLEROSIS 21 
PROBLEMS IN PERIPHERAL NERVE REGENERATION 23 
PERIPHERAL NERVES MUST OVERCOME MANY OBSTACLES FOR PROPER REGENERATION 23 
PERIPHERAL NERVE REGENERATION IS FURTHER IMPAIRED BY AGE AND DISEASE 26 
THERAPEUTIC OPTIONS FOR ENHANCING AXONAL REGENERATION ARE ABSENT 26 
BETA SECRETASE AS A NOVEL REGULATOR OF PERIPHERAL NERVE REGENERATION 27 
REDUCED BACE1 ACTIVITY LEVELS IMPROVE PERIPHERAL NERVE REGENERATION 27 
BACE1 SUBSTRATES THEMSELVES INFLUENCE AXONAL REGENERATION 28 
BETA SECRETASE INHIBITORS AS A POTENTIAL THERAPEUTIC STRATEGY FOR 
ENHANCING PERIPHERAL NERVE REGENERATION 31 
BACE1 INHIBITOR DEVELOPMENT 31 
BACE1 INHIBITORS DEVELOPED FOR AD HAVE GOOD SAFETY PROFILES 32 
POTENTIAL ISSUES SURROUNDING THE USE OF BACE1 INHIBITORS FOLLOWING ACUTE PERIPHERAL NERVE 
INJURIES 33 
BACE1 INHIBITOR TREATMENT MAY AVOID AXONAL GUIDANCE ISSUES IN ADULTS 36 
BACE1 INHIBITORS MAY BE USEFUL IN EARLY STAGE PERIPHERAL NEURODEGENERATIVE DISEASES 37 
CONCLUDING REMARKS OF THE INTRODUCTION 37 
CHAPTER 2: OVEREXPRESSION OF BACE1 LEADS TO REDUCED 
PERIPHERAL NERVE REGENERATION AFTER ACUTE NERVE INJURY 39 
INTRODUCTION TO CHAPTER 2 39 
RESULTS 40 
OVEREXPRESSION OF BACE1 DOES NOT ALTER UNINJURED AXON MORPHOLOGY OR PHYSIOLOGY 40 





BACE1 OVEREXPRESSION IMPAIRS AXONAL REGENERATION AS EARLY AS 3 DAYS AFTER INJURY 46 
OVEREXPRESSING BACE1 LEADS TO IMPAIRED AXONAL REGENERATION 10 DAYS AFTER INJURY 49 
BACE1 OVEREXPRESSION REDUCES REINNERVATION OF THE GASTROCNEMIUS MUSCLE 15 DAYS AFTER 
INJURY 52 
OVEREXPRESSION OF BACE1 CAUSES A DELAY IN THE LONG-TERM RECOVERY OF THE CMAP 55 
SUMMARY OF CHAPTER 2 59 
CHAPTER 3: DECREASED BACE1 ACTIVITY ENHANCES PERIPHERAL 
NERVE REGENERATION FOLLOWING A NERVE CRUSH INJURY 60 
INTRODUCTION TO CHAPTER 3 60 
RESULTS 61 
BACE1 INHIBITORS TARGET BACE1 ACTIVITY 61 
BACE1 INHIBITION ENHANCES NEURITE BRANCHING AND OUTGROWTH IN VITRO 64 
BACE1 INHIBITORS DO NOT ALTER NORMAL, UNINJURED AXON MORPHOLOGY 65 
BACE1 INHIBITION ENHANCES AXON REGENERATION AFTER A SCIATIC NERVE CRUSH INJURY 69 
SUMMARY OF CHAPTER 3 73 
CHAPTER 4: AXONAL SPROUTING FOLLOWING A PARTIAL NERVE 
INJURY IS ENHANCED BY BACE1 INHIBITION 75 
INTRODUCTION TO CHAPTER 4 75 
RESULTS 76 
PARTIAL NERVE TRANSECTIONS CAN BE PERFORMED IN THE LATERAL-THORACIC NERVE-CUTANEOUS 
MAXIMUS MUSCLE SYSTEM 76 
THE CMM IS A THIN MUSCLE EXCLUSIVELY COMPRISED OF TYPE II MUSCLE FIBERS 78 
WHOLE-MOUNTED LTN–CMM CAN BE STAINED WITH ANTIBODIES 82 




SUMMARY OF CHAPTER 4 88 
CHAPTER 5: MONITORING PERIPHERAL NERVE DEGENERATION IN A 
CHRONIC NEURODEGENERATIVE DISEASE MODEL 89 
INTRODUCTION FOR CHAPTER 5 89 
RESULTS 90 
NEITHER AXON NOR TERMINAL DEGENERATION WAS DETECTED AT 30 DAYS OF AGE 90 
MARKED DEGENERATION APPEARS AT THE CAUDAL REGION BY 60 AND 90 DAYS 93 
PHYSIOLOGICAL CHANGES AT THE DISTAL LTN OCCURS EARLIER THAN THE SCIATIC NERVE 98 
LIMITED SPROUTING OF THE SURVIVING LTN AXONS 100 
SUMMARY OF CHAPTER 5 102 
CHAPTER 6: BACE1 INHIBITORS AS POTENTIAL THERAPEUTICS TO 




BACE1 INHIBITORS IMPROVE MUSCLE INNERVATION AND ELECTROPHYSIOLOGICAL VALUES IN AN ALS 
MOUSE MODEL AFTER 1 MONTH OF TREATMENT 104 
BACE1 INHIBITOR TREATMENT ONLY IMPROVES MORPHOLOGICAL REPAIR AFTER 2 MONTHS OF TREATMENT
 109 
AXONAL SPROUTING IS ENHANCED BY REDUCING BACE1 ACTIVITY 112 
L1/CHL1 EXPRESSION LEVELS ARE INCREASED IN SOD1G93A MICE FOLLOWING BACE1 INHIBITION 114 
SUMMARY OF CHAPTER 6 115 




INCREASED BACE1 ACTIVITY LEVELS ARE DETRIMENTAL TO PERIPHERAL NERVE 
REPAIR 118 
POTENTIAL BACE1 MECHANISMS 119 
BACE1 ACTIVITY LEVELS MAY BE FURTHER COMPLICATING REPAIR IN DISEASE AND 
AGEING 120 
THE LTN-CMM SYSTEM IS USEFUL FOR STUDYING PERIPHERAL NERVE REPAIR 
FOLLOWING ACUTE NERVE TRAUMA AND IN NEURODEGENERATIVE DISEASES 121 
BACE1 INHIBITORS AS A THERAPY FOR TRAUMATIC PERIPHERAL NERVE INJURIES 125 
EARLY TREATMENT WITH BACE1 INHIBITORS IMPROVES CMM INNERVATION IN AN 
ALS MOUSE MODEL 128 
FINAL CONCLUSION 130 
CHAPTER 8: METHODS 131 
ANIMALS 131 
BACE1 OVEREXPRESSION EXPERIMENTS 131 
BACE1 KO EXPERIMENTS 131 
INJURY EXPERIMENTS IN WT MICE 132 
SOD1 EXPERIMENTS 132 
MOUSE PERFUSION 133 
TISSUE PROCESSING FOR LIGHT AND ELECTRON MICROSCOPY 134 
NERVE INJURY PROTOCOLS 135 
SCIATIC NERVE CRUSH 135 
SCIATIC NERVE TRANSECTION 135 
PARTIAL LTN TRANSECTION 136 




ELECTROPHYSIOLOGY PROTOCOLS 137 
SCIATIC NERVE ELECTROPHYSIOLOGY 137 
LTN–CMM ELECTROPHYSIOLOGY 138 
TISSUE STAINING 139 
CULTURED DRG NEURONS 139 
SCIATIC NERVE STAINING 140 
GASTROCNEMIUS MUSCLE STAINING 140 
LTN–CMM STAINING 141 
MUSCLE TYPE STAINING 141 
REGENERATION ANALYSIS 142 
SCIATIC NERVE REGENERATION 142 
EARLY REGENERATION ANALYSIS 142 
MACROPHAGE QUANTIFICATION 143 
NMJ REINNERVATION 143 
AXONAL SPROUTING 144 
WESTERN BLOT 144 











List of Figures 
Fig. 1. BACE1 activity levels inversely regulate peripheral nerve repair. .............................. 3 
Fig. 2. Peripheral nerves can regenerate by sending out sprouts from the proximal stump. 10 
Fig. 3. Intact axons can send out axonal sprouts following partial nerve injuries. ............... 12 
Fig. 4. Problems in peripheral nerve regeneration................................................................. 25 
Fig. 5. Potential mechanism for how BACE1 activity levels regulate peripheral axon growth.
 ................................................................................................................................................. 30 
Fig. 6. BACE1 overexpression does not affect nerve morphology and electrophysiology. ... 42 
Fig. 7. BACE1 overexpression does not alter degeneration 5 days after complete sciatic 
nerve transection. .................................................................................................................... 44 
Fig. 8. BACE1 overexpressing mice have reduced early regeneration 3 days after a sciatic 
nerve crush. ............................................................................................................................. 47 
Fig. 9. Fewer axons extend distally from the crush site in BACE1 transgenic mice 3 days 
following injury. ...................................................................................................................... 49 
Fig. 10. BACE1 overexpression hinders axonal regeneration 10 days after sciatic nerve 
crush. ....................................................................................................................................... 50 
Fig. 11. Neurofilament staining with BACE1 overexpression is reduced 15 days following a 
sciatic nerve crush. .................................................................................................................. 52 
Fig. 12. BACE1 overexpression reduces NMJ reinnervation in the gastrocnemius muscle 
15 days after sciatic nerve crush. ............................................................................................ 53 
Fig. 13. BACE1 overexpression leads to delayed functional recovery after a sciatic nerve 
crush. ....................................................................................................................................... 57 
Fig. 14. Oral BACE1 inhibitors reduce full length APP. ....................................................... 62 
Fig. 15. Cultured adult mouse neurons have enhanced neurite branching after BACE1 




Fig. 16. BACE1 inhibitors do not alter normal axon morphology and physiology. .............. 67 
Fig. 17. BACE1 inhibitors enhance axonal regeneration following a sciatic nerve crush.  .... 70 
Fig. 18. BACE1 inhibition enhances functional repair following a sciatic nerve crush injury.
 ................................................................................................................................................. 72 
Fig. 19. Utilizing the LTN-CMM system to perform partial nerve transections. .................. 77 
Fig. 20. The CMM is exclusively comprised of type II muscle fibers. ................................... 80 
Fig. 21. Reliable antibody staining of the neuromuscular synapse components in the whole, 
intact CMM. ............................................................................................................................ 83 
Fig. 22. Genetically knocking out BACE1 enhances axonal sprouting following a partial 
nerve transection. .................................................................................................................... 85 
Fig. 23. BACE1 inhibitors enhance terminal axonal sprouting following a partial nerve 
injury. ...................................................................................................................................... 87 
Fig. 24. No evidence of axonal degeneration in 30-day-old SOD1 mice. ................................ 91 
Fig. 25. Axonal degeneration is evident by 60 days in SOD1 mice at the caudal site but not 
the rostral site.......................................................................................................................... 94 
Fig. 26. Axonal degeneration is apparent at the rostral site at 90 days of age in SOD1 mice.
 ................................................................................................................................................. 96 
Fig. 27. The sciatic nerve shows a decrease in CMAP amplitude at 90 days. ........................ 99 
Fig. 28. SOD1 mice show very limited axonal sprouting...................................................... 101 
Fig. 29. 1 month MBI-9 BACE1 inhibitor treatment improves morphological and 
physiological repair in SOD1 mice. ...................................................................................... 106 
Fig. 30. 1 Month of LY2886721 BACE1 inhibitor treatment enhances morphological and 
electrophysiological values in SOD1 mice. ........................................................................... 108 
Fig. 31. 2 month Merck BACE1 inhibitor treatment improves morphological repair but not 




Fig. 32. BACE1 inhibition enhances axonal sprouting in disease. ....................................... 113 
Fig. 33. BACE1 inhibition alters L1/CHL1 expression levels in SOD1 mice....................... 115 
 
List of Tables 






















Chapter 1: Introduction 
Introduction 
 One of the many unsolved mysteries in neuroscience is the unknown reasons why 
the peripheral nervous system (PNS) is able to regenerate its axons following injury 
while the central nervous system (CNS) has limited growth capacity. The search for 
understanding this fundamental difference between the peripheral and central nervous 
systems has led to many discoveries of the cellular changes, differential gene expression, 
and pathways that regulate how the PNS is able to regenerate. There is now a good 
understanding of the steps required for the peripheral nerve to begin to regenerate and 
how these steps differ from the CNS. After axonal injury, the axolemma begins to 
degenerate and the myelin sheath breaks up. Following this degeneration, axonal and 
myelin debris is cleared in order to make space for regenerating axons to grow. In the 
PNS, macrophages, and to some extent Schwann cells, the myelinating cells in the PNS, 
begin to phagocytose axonal and myelin debris (1-4). In the CNS, resident microglia, and 
an influx of blood-borne macrophages, are responsible for debris clearance, however, 
there is some evidence that the CNS response to debris clearance is very slow and 
contributes to the limited axonal regeneration (5-7). Next, the supporting cells need to 
provide aid to the regenerating axons by guiding them towards the correct end target. The 
Schwann cells of the PNS carry this out by undergoing dedifferentiation and creating 
Schwann cell tubes, called Bünger bands, for which the regenerating axons can enter and 
grow through before reaching their target and getting remyelinated (8-10). In the CNS, 




which make up a majority of the glial scar (8). This process is detrimental to axonal 
regeneration and provides a significant barrier for repair following CNS trauma. Another 
step that must occur for successful regeneration is when neurons and supporting cells 
alter their gene expression profiles to a pro-regenerative state. The cells of the PNS 
upregulate various growth factors, transcription factors, and adhesion molecules, 
collectively termed regeneration associated genes (RAGs), which all work together to 
enhance axonal outgrowth (11-14). On the other hand, CNS cells generally do not 
express high levels of RAGs. In fact, oligodendrocytes, responsible for myelination in the 
CNS, express various myelin-associated inhibitors, such as Nogo-A and myelin-
associated glycoprotein, while neurons express axon regeneration inhibitor molecules, 
like repulsive guidance molecule and Semaphorin A (11).   
  Our lab has discovered a novel role of beta-site APP-cleaving enzyme 1 
(BACE1), or beta secretase, in regulating peripheral axonal regeneration. BACE1 is a 
transmembrane protease that is involved in the cleavage and processing of a wide variety 
of membrane bound proteins (15-23). What is interesting with regard to peripheral nerve 
regeneration is that many of BACE1’s substrates have been implicated in the regulation 
of axonal regeneration and neurite outgrowth. Some have even been identified as genes 
which are upregulated following nerve injury. We have demonstrated, using BACE1 KO 
mice, that lacking beta secretase enhances peripheral axonal regeneration following 
axonal injury. When beta secretase was genetically knocked out, we observed an 
increased number of regenerating axons following a sciatic nerve crush (24-26). This 
finding has led us to hypothesize that BACE1 activity levels may inversely influence 





Fig. 1. BACE1 activity levels inversely regulate peripheral nerve repair.  
Hypothetically, we propose that with low levels of BACE1 activity, peripheral nerve repair is 
accelerated. When BACE1 activity levels are high, axonal repair is reduced. We hypothesize that 
this relationship is on a sliding scale where changes in BACE1 expression have a small effect on 
repair process effectiveness. 
 
Despite peripheral nerves' ability to regenerate, the outcome of this regeneration 
is often poor and insufficient (9, 10, 27, 28). Peripheral nerve regeneration must 
overcome many obstacles, including slow regeneration rates, inefficient axonal guidance, 
and the degeneration of supporting cells’ end targets. Currently, the only available 
treatment option for patients is the surgical reconnection of the nerve (29). Various novel 
therapeutic options are being explored to improve outcomes such as enhanced nerve 
conduits, stem cell treatments, and small molecule drugs to enhance regeneration (13, 
29). Our recent data, together with the greater body of research on BACE1’s substrates’ 
impact on axonal growth, points towards a possible novel application for BACE1 




Beta secretase and its many substrates 
Beta-site APP cleaving enzyme 1 (BACE1) 
 BACE1 mRNA is widely expressed in many tissues throughout the body, 
however, the highest expression levels are found in the brain and pancreas (15, 30). In the 
normal CNS, BACE1 expression is highly localized to neuronal tissue and is not 
expressed in the surrounding glial cells (30). The expression mRNA pattern of BACE1 is 
closely correlated with BACE1 activity (30). Interestingly, BACE1 activity levels in the 
pancreas are rather low compared with the levels of mRNA expression. It was later 
determined that the BACE1 mRNA in the pancreas was actually a splice variant missing 
most of exon 3 which abolished its enzymatic ability (31, 32). Two inactive splice 
variants of BACE1 have been identified, with both being expressed in the pancreas and 
only 1 being expressed in the brain (32).  
BACE1 is an approximately 70 kDa protein whose structure consists of a single 
transmembrane domain with a luminal Asp32-Asp228 catalytic domain (33, 34). Since 
the optimal pH range for BACE1 activity is fairly acidic (15, 35), it primarily localizes to 
the Golgi apparatus and endosomes (16, 17, 36, 37). BACE1 is first synthesized as a pro-
enzyme in the endoplasmic reticulum (38). On its way to the Golgi apparatus, the pro-
enzyme gets glycosylated and acetylated before carbohydrates are attached and the N-
terminal prodomain is trimmed (38). BACE1 is then cycled between the cell surface and 







BACE1’s role in amyloid precursor protein processing 
 BACE1 has been well studied in the context of AD as it is one of the main 
enzymes responsible for generating amyloid beta plaques (A), a pathological hallmark 
of the disease (15-17, 39-41). In order to generate A, BACE1 cleaves amyloid precursor 
protein (APP) into a membrane bound C-terminal fragment (CTF) and a soluble APP 
fragment. The CTF is then further cleaved by gamma secretase to generate the A 
fragment that then goes on to aggregate and form plaques. A reduction in beta secretase 
activity, either genetically or pharmacologically, leads to a decrease in the production of 
A (15, 39-42). Conversely, when human BACE1 is overexpressed in mice, APP 
processing is increased leading to amyloid deposition and synaptic defects or 
neurodegeneration (43, 44). The fact that BACE1 is one of two important enzymes 
involved in generating A plaques has led many drug companies to investigate BACE1 
inhibitors as potential therapeutics for AD (42, 45-48). This large interest in inhibiting 
BACE1 has led many to ask the question, what other substrates, if any, does BACE1 
cleave?  
 
BACE1 impacts peripheral myelination via neuregulin-1 type III 
As it turns out, BACE1 is a rather promiscuous enzyme and over 60 putative 
substrates have been identified (18, 49-53). Fortunately, despite the large number of 
substrates, BACE1 knock out mice are viable, with some moderate behavioral 
phenotypes (39-41). One of the more striking phenotypes observed was the reduction in 
the myelination of the peripheral nerves in these mice. The thickness of the myelin sheath 




unmyelinated groups of axons, called Remak bundles, can be seen in nerve bundles in the 
periphery (22, 23, 54, 55). While reduced peripheral myelination is cause for concern 
when treating patients with BACE1 inhibitors, this phenotype appears to mostly be a 
developmental issue. When adult mice are given a BACE1 inhibitor, others (46) and our 
lab (unpublished observation) have observed that the myelination of uninjured peripheral 
axons is not changed. This observation of altered myelination gave a clue as to what other 
substrates BACE1 may be cleaving. As it turns out, BACE1 is involved in the cleavage 
of neuregulin-1 type III (NRG1) (22, 54). NRG1 type III is the molecule responsible for 
determining the levels of myelination in the peripheral nervous system (56, 57). 
Fortunately, its cleavage and activation is not solely dependent on BACE1 as it is also 
cleaved by ADAM17 (58). This parallel pathway allows for some myelination to occur 
and may be the reason for the presence of some myelination in total KO mice.  
 
BACE1 activity influences axonal guidance via multiple adhesion molecules 
Another phenotype that has caused some concern for BACE1 inhibitor use is the 
potential issues with axonal guidance. In BACE1 KO mice, there appears to be some 
defects in axonal connections in the central nervous system, most notably in the olfactory 
bulb and mossy fiber projections (59). This finding has led to the speculation that BACE1 
inhibitors may negatively impact memory and learning by impairing synaptic plasticity. 
Since some of the potential BACE1 substrates are involved in cell-cell adhesion, such as 
neural cell adhesion molecule 1 (NCAM1) (18), it likely follows that this may be the 
reason behind the axonal guidance issues. Indeed, two of BACE1’s identified substrates, 




(49). These molecules are members of the immunoglobulin superfamily and have been 
identified as being important in proper neurogenesis. A loss of L1 or CHL1 leads to 
behavioral abnormalities and decreased cognitive function in mice (61, 62). There are 
also known mutations in humans, which lead to mental retardation as well as 
schizophrenia (63-66).  
Another protein that was identified as a BACE1 substrate is contactin-2, also 
known as Axonin-1 or transiently expressed axonal surface glycoprotein-1 (TAG-1) (60). 
This protein is also a member of the immunoglobulin superfamily and is expressed on the 
surface of axons as well as the Schwann cells of the PNS (67, 68). A loss of contactin-2 
led to a reduced axonal growth speed and impaired guidance in zebrafish (69). Following 
a sciatic nerve crush, contactin-2 was found to be upregulated in Schwann cells near the 
lesion (70). BACE1 cleavage of contactin-2 also appears to have a negative impact on the 
level of contactin-2 found on the cell surface of primary mouse neurons (71). 
One more BACE1 substrate that has been identified as being an important 
regulator for neurite outgrowth is Seizure-related gene 6 (Sez-6)(60). It has been 
implicated as having an important role in regulating neurite outgrowth and connectivity 
in the developing neocortex. Cultured cortical neurons from Sez-6 null mice showed 
more extensive neurite branching, however, they also had a reduction in neurite length 
(72). Another group also observed a decrease in neurite length when administering an 
shRNA against Sez-6 in PC12 cells treated with NGF (50).  
As many of BACE1’s substrates appear to be important in regulating axonal 




implications going beyond AD. Our lab has been studying the effects of BACE1 activity 
levels on the efficacy of peripheral nerve regeneration following acute nerve injury. 
 
BACE2 
 In addition to the identification of BACE1, there was also the discovery of a 
closely related homolog, named BACE2. Like BACE1, BACE2 is a membrane bound 
aspartyl protease with a very similar structure (73). BACE2 is also expressed in a wide 
variety of cell types, however, its expression levels in the brain are very low and only in 
very specific regions of the brain (38). BACE2 expression appears to be higher in the 
pancreas (74) and is involved in proper β cell function (75). BACE2 also differs in the 
way that it cleaves APP in a more α-secretase manner than a β-secretase manner (76). In 
addition to the Asp+1 cleavage site, BACE2 can also cleave at Phe+19 and Phe+20, 
indicating that it may have different processing preferences than BACE1(77). Another 
way that BACE2 differs is that it appears to regulate melanocyte function in zebrafish 
and hair pigmentation in mice (73, 78, 79). BACE2 knockout zebrafish also do not have 
any defects in the myelination of their nerves unlike BACE1 knockouts indicating that 
BACE2 most likely is not involved in myelination (78). All of this data points towards 
BACE2 having distinct functions from BACE1. 
  
How do peripheral nerves regenerate? 
The type and extent of peripheral nerve injury affects regeneration efficacy 
 The type and severity of a nerve injury can have a profound effect on how 




injuries, such as a nerve crush, the endoneural tube and basement membrane surrounding 
the axon remains intact, while the axon itself becomes disconnected. The regenerating 
axonal sprouts may be able to navigate their way back into the denervated Schwann cell 
tubes still connected to the proximal portion of the nerve. This is advantageous as the 
neural tube acts as a highway for the axon to be properly guided towards its appropriate 
target (Figure 2). In more severe injuries, such as a partial or complete nerve transection, 
the Schwann cell tube is no longer connected and the proximal axonal sprout can have a 
difficult time correctly navigating towards the open end of the tube. Depending on the 
location and extent of the nerve transection, the difficulty that proximal axonal sprouts 
have to re-enter the distal tube may leave the target organ insufficiently innervated for an 
extended period or, in the worst case, permanently denervated. Axonal sprouts that are 
unable to reach the vacated Schwann cell tubes and reinnervate the target muscle are 
generally pruned back to the main axon branch. In some cases, the unguided sprout can 









Fig. 2. Peripheral nerves can regenerate by sending out sprouts from the proximal stump.  
A) Uninjured peripheral axons (dark gray) are wrapped in a discontinuous myelin sheath (dark 
blue) generated by closely associate Schwann cells (light blue). Their nuclei are centrally located 
with disperse Nissl staining bodies (black dots) B) Following a nerve crush injury, the axonal 
portion distal to the crush site degenerates and the cell body carries out a chromatolytic response  
where the nucleus becomes peripherally located with chromatolytic bodies nearby (represented 
by the black dots around the nucleus). The proximal stump connected to the cell body will begin 
to send out a small axonal sprout through the crush site (yellow lightning bolt) directed to the 
now vacated Schwann cell tube made up of many proliferating Schwann cells (empty blue cells) 
encapsulated by the still intact basement membrane (gray dots). C) If the sprout is able to connect 
with the Schwann cell tube, it begins to elongate into the tube and grow towards the end target 






Axonal sprouting from neighboring intact axons contributes to reinnervation 
 When the distal portion of the axon is unable to regenerate, or the area of 
denervation is too far away from the proximal site, neighboring intact axons can also 
send out axonal sprouts from their own axon to reinnervate nearby denervated 
neuromuscular junctions (NMJs) as an alternative process to enhance target organ 
reinnervation (80). The terminal Schwann cell sitting on the denervated NMJ will 
become activated and send out numerous processes (81-84). Eventually, a process will 
connect with a nearby intact axonal sprout and create a bridge between the intact axonal 
sprout and the denervated NMJ. This then allows the axonal sprout to be guided towards 
the denervated NMJ where it can then reinnervate the NMJ. These axonal sprouts can 
form from multiple regions along intact axons (Figure 3) (85). Axonal sprouts, termed 
nodal sprouts, can emerge along the main axon branch at the nodes of Ranvier, where the 
myelin sheath does not cover the axon. The sprouts can also emerge closer to the NMJs, 
called pre-terminal sprouts, where the myelin sheath ends just before the NMJ to allow 
for the terminal bouton to interact with the NMJ. Finally, there can also be terminal 
axonal sprouts which come directly from the terminal bouton innervating the NMJ. 
Terminal axonal sprouts are easiest to identify as the normal morphology of the terminal 
bouton at the NMJ only has one axonal connection (85). In cases of disease or injury, 





Fig. 3. Intact axons can send out axonal sprouts following partial nerve injuries. 
A) When a nerve is partially injured, only some of the axons degenerate, as depicted by the empty 
Schwann cell tubes (light blue). A few intact axons (dark green) remain connected to their targets, 
in this case the NMJ (red), and can also be myelinated (dark blue). B) The intact axon has the 
option to send out axonal sprouts (lime green) to reinnervate the denervated NMJs nearby and can 
do so in three different ways. The first is a nodal sprout (I), where the sprout originates at the 
nodes of Ranvier. The second way is a pre-terminal sprout (II) that branches out from the 
unmyelinated portion of the axon just before synapsing on the NMJ. The final way for an axon to 
sprout is to send out a terminal sprout directly from the terminal bouton portion at the NMJ (III). 
 
While axonal sprouting to neighboring targets is an important process to maintain 
connections under conditions of axonal and neuronal cell loss, it is a limited process. The 
size of any particular motor unit is bound by the surviving neuron’s ability to 
metabolically sustain such a large number of connections (86, 87). Eventually, the motor 
unit becomes too large and the neuron cannot afford to continue to sprout axons. In 




muscle fiber types have varying sprouting capacities (88). Those motor axons innervating 
fast-fatigable, type IIb muscle fibers had a much lower terminal sprouting response to 
Botulinum A toxin induced terminal sprouting than the slow-twitch, type I muscle fibers 
(88). This finding may further complicate the efficacy of axonal sprouting depending on 
which nerves were injured, as some muscles are predominantly type IIb muscle fibers, 
such as the extensor digitorum longus (EDL) (89), and may not be as effectively 
reinnervated as a type I muscle, like the soleus muscle (89). 
 
Regeneration associated genes 
 In order to initiate axonal sprouting, the gene expression profiles change to a pro-
regenerative state. With the recent advances of microarrays, and now RNA Seq, the 
number of identified genes that are differentially expressed following acute peripheral 
nerve injury is ever growing (12, 14, 90). Many of these regeneration associated genes 
(RAGs) are anti-apoptotic, transcription factors, or are involved in cytoskeleton 
remodeling, cell growth, and cell-cell adhesion. In order to accommodate the rapid 
increase in transcription, many transcription factors become upregulated following injury 
and have been observed to enhance regeneration, with c-Jun, STAT3 and ATF3 being 
notable (12, 91-93). Many kinase cascades, such as the MAPK pathway, have been 
identified as RAGs, however, there is some debate over whether these pathways are 
involved in adult peripheral regeneration (94). Neurotrophic factors, such as IGF1, IGF2, 
NGF and BDNF, are also increased following injury and have been shown to positively 
impact axonal regeneration (95-97). There is also a large upregulation of the expression 




in the interaction between the cell surface and the cytoskeletal components of the cell, 
such as GAP43, are upregulated following injury in order to prepare for the large 
cytoskeleton remodeling involved in axonal outgrowth (99-101). The genes listed here 
are just a snapshot of the large number of genes whose expression levels are altered in 
order for neurons to undergo the extensive and complicated process of regeneration. 
 
Modeling peripheral nerve injuries in mice 
The sciatic nerve is a simple model to study nerve crush injuries 
 In order to study how BACE1 activity levels can influence peripheral nerve 
regeneration following an injury we need reliable models that reflect the various ways 
peripheral nerves can be injured. One of the ways a peripheral nerve can be injured is by 
crushing the nerve. This type of injury leads to the degeneration of the axon distal to the 
crush site and the breakdown of the myelin sheath. The Schwann cells and endoneural 
tube, however, are spared and provide a supportive track for the proximal portion of the 
axon to regenerate towards its normal end target (102). In order to easily perform a nerve 
crush, the most widely used model is the sciatic nerve crush in either a mouse or rat. This 
is easily performed by making a small incision along the thigh to expose the sciatic nerve 
and applying pressure on the nerve between a pair of tweezers or tying a suture tightly 
around the nerve. The recovery following a sciatic nerve crush injury can then be 
monitored both morphologically and functionally. Morphologically, one can look at the 
sciatic nerve itself and quantify the number of regenerating axons present in a cross 
section of the nerve (25, 103, 104). Additionally, the extent of reinnervation of the 




103-105). This system also provides the opportunity to monitor functional recovery by 
recoding the recovery of the compound muscle action potential (CMAP) from the various 
muscles innervated by the sciatic nerve (102, 103). 
 While the sciatic nerve provides an easy model to perform a reliable nerve crush 
injury, it does have some limitations. Since it is a mixed nerve of autonomic, sensory, and 
motor fibers, it can be difficult to determine whether there is a difference in regeneration 
between fiber types. To further compound this difficulty, there is some evidence that both 
motor and sensory fibers can be inappropriately recruited to target organs, however, this 
error can be corrected by pruning the aberrant innervation provided sufficient 
reinnervation has occurred (106, 107). Another issue is that the muscles which are 
innervated by the sciatic nerve are too large to completely stain and clearly image. 
Typically, the muscles need to be sectioned before staining in order to properly visualize 
the axons and NMJs. This is a confounding issue when trying to study axonal sprouting 
as it becomes rather tedious to reconstruct the muscle and trace the origin and end point 
of potential axonal sprouts. This can be partly improved by using the extensor digitorum 
longus (EDL) or tibialis anterior (TA) muscles as they are thinner than the gastrocnemius 
muscle and can be whole mounted (104, 105), however, the depth of staining penetration 
and imaging can be rather poor and may lead to difficulty tracing the extremely thin 
axonal sprouts. Finally, reliably performing partial nerve injuries in the sciatic nerve is 
fairly difficult. Traditionally, partial nerve injuries are performed by tightly tying a suture 
around 1/2 to 1/3 of the sciatic nerve or cutting half of the sciatic nerve (108, 109). 
However, it is rather difficult to injure a consistent number of axons as there is no way to 




which a partial nerve transection can be performed using the sciatic nerve is to carry out a 
ventral root transection (110). While this procedure is able to produce a more reliable 
partial nerve injury, it is difficult to perform as the ventral roots are situated very close to 
the spinal cord and requires rather tricky surgical techniques to be performed. 
 
Utilizing the Lateral Thoracic Nerve – Cutaneous Maximus Muscle system to model 
partial nerve injuries 
 While sciatic nerve crushes tend to be easy to perform in the mouse, these types 
of injuries tend to be less severe due to the endoneural tube and Schwann cell tube 
remaining connected to the portion of the nerve proximal to the crush site. A nerve 
axotomy, whether complete or partial, typically does not regenerate as well because the 
proximal portion of the nerve is no longer connected to the distal portion. In the case of a 
partial nerve transection, the intact axons respond to the denervation by sending out 
collateral axonal sprouts in an attempt to reinnervate portions of the denervated target 
organ. As discussed in the previous section, performing a partial nerve transection on the 
sciatic nerve has many technical issues. A more reliable model for performing partial 
nerve transections is needed before beginning to investigate whether pharmacological 
interventions can alter axonal sprouting in response to a partial nerve injury. Therefore, it 
would be beneficial to utilize a muscle-nerve system that can overcome many of the 
limitations of the sciatic nerve model. 
 The cutaneous maximus muscle (CMM) – lateral thoracic nerve (LTN) system 
may be the model that provides some of the answers to the problems of performing a 




system (111). The LTN originates from the C7-T1 spinal nerves, exiting out from the 
brachial plexus towards the shoulder and eventually on to innervate the CMM. The CMM 
itself spans the entire back of the mouse and is located subdermally, in order to control 
the dorsal twitch reflex. The three main branches of the LTN are easily isolated by 
making a small incision along the ventral edge of the scapula and gently teasing apart the 
muscles (111). The relatively conserved organization of the LTN branches and the ease 
with which they can be accessed may offer a more consistent model for performing 
partial nerve transections. This would be beneficial as variable amounts of degeneration 
may have potential effects on the extent of axonal sprouting since axons only send out 
collateral sprouts in response to nearby degeneration.  
Normally, the LTN extends caudally down the CMM, innervating various muscle 
fibers along the way. The left and right inputs from the spinal cord do not cross the 
midline and allows for one side to be used as an internal control when injuring one side 
of the LTN. Of particular note is that the LTN is a purely motor nerve, unlike the sciatic 
nerve, and the dorsal cutaneous sensory nerve is separated from the LTN. When 
removing the dorsal skin, the CMM is removed along with it as it lies directly below the 
dermis. The sensory nerves can then be removed by carefully removing the connective 
tissue on top of the CMM, with the skin side facing down. This separation of sensory and 
motor fibers allows for only the motor LTN nerves to be injured and may help to reduce 
confusion between sensory and motor sprouting when imaging the CMM.  
In addition to being able to separate the sensory nerves, the CMM can also be 
whole mounted onto a slide and imaged because the CMM is an extremely thin muscle, 




advantages over the muscles being innervated by the sciatic nerve. Firstly, it is quite easy 
to completely stain the CMM and image through the entire muscle. Secondly, the ability 
to image through the intact muscle allows for easy tracing of the beginning and end 
points of potential axonal sprouts. Lastly, because the LTN enters the CMM near the 
shoulder and spans the length of the mouse, it is possible to investigate the time course of 
regeneration in some of the shortest and longest axons in the mouse body. By contrast, in 
order to perform a similar experiment using the sciatic nerve, one would need to image 
multiple different muscles located in different regions of the body to get the longest and 
shortest axons from the sciatic nerve. 
 
Examples of diseases that lead to peripheral nerve degeneration 
 In addition to acute trauma, peripheral nerves can also be injured as a result of 
neurodegenerative diseases and peripheral neuropathies. These diseases provide a more 
chronic model of peripheral nerve degeneration as many undergo a progressive loss of 
peripheral nerves as the disease advances. Here we outline a few key diseases which lead 
to progressive peripheral nerve degeneration and the mouse models used to study them. 
 
Charcot-Marie-Tooth disease  
 Another disease which can lead to progressive peripheral axonal loss is Charcot-
Marie-Tooth disease (CMT). This disease is characterized by extensive myelin loss and 
axonal degeneration. Patients typically present with distal sensory loss and muscle 
weakness, as well as reflex abnormalities. CMT can be broadly categorized into two main 




axonal defects (CMT2) (113). Despite this difference, both forms of the disease 
ultimately lead to axonal degeneration (114). Over the years, many mutations have been 
identified with respect to the pathophysiology observed in CMT (113, 115). Mouse 
models have been generated to study the disease progression using many of the more 
common mutations found to be associated with both CMT1 and CMT2 (116). One such 
mouse model is the Trembler J mouse, which expresses a mutant form of the peripheral 
myelin protein 22 (PMP22) and is a model for CMT1 (117, 118). These mice have 
myelin deficiencies and extensive peripheral axon degeneration, as well as abnormal 
NMJs (111, 117, 119). Other mouse models for CMT1 are those which express mutant 
connexin 32 (GJB1 gene) or myelin protein zero (MPZ gene) (116). For CMT2, 2 main 
mouse models have been generated. One encodes a mutant neurofilament light gene 
(NEFL) and the other a mutant heat shock protein B1 (HSPB1) (116). Unlike ALS, CMT 
involves both motor and sensory axons which provides the ability to study the 
degeneration of both sensory and motor axons. The extent of axonal regeneration of both 
sensory and motor fibers, both endogenous sprouting in the disease state as well as 
whether any therapeutic strategies can increase sprouting, can be studied in these models. 
Another interesting aspect to using CMT models is that there are also Schwann cell 
defects which may impact the ability of the axons to extend out axonal sprouts and 
highlight any importance in the role of Schwann cell involvement in axonal sprouting. 
 
Diabetic peripheral neuropathies 
 Diabetic peripheral neuropathies (DPN) are characterized as a length dependent, 




degeneration, diabetic patients also have impaired axonal regeneration following a nerve 
injury, such as when the skin is cut (120-122). Since sensory nerves are the most 
susceptible to DPN, many patients experience extremely painful symptoms, such as 
burning, paraesthesia, or a stabbing pain. In addition to these painful symptoms, patients 
also have impaired abilities to detect small cuts on their extremities. This defect can 
eventually lead to infection and ultimately limb amputation if the patient is not attentive 
to checking extremities for cuts and accounts for a majority of limb amputations in the 
US. Currently, it is believed that both vascular changes as well as metabolic dysfunction 
in response to dysregulated glucose control play a role in the pathophysiology leading to 
the degeneration of peripheral nerves (123). The idea that hyperglycemia may be the 
main driver of DPN may not be completely correct. Type I diabetics are able to reduce 
their incidence of DPN more than Type II diabetics by controlling their glucose levels 
and many patients develop DPN despite having good control over their glucose levels 
(124). 
While the majority of diabetes cases are not closely associated with specific 
mutations, a few mouse and rat models have been created. The most commonly used 
models are those that mimic type II diabetes as that is the most common form of diabetes. 
The most common genetic mouse models are the ob/ob mice, with mutations in leptin, 
and the db/db mice, with mutations in the leptin receptor, that both have impaired leptin 
signaling (125). In addition to mutant mouse models, it is also possible to generate a 
diabetic phenotype by placing the mice on a high-fat diet, which then go on to develop 
diet-induced obesity (125). All three mouse models recapitulate many of the symptoms 




morphology is evident, and they have reduced reactions to thermal stimuli (125, 126). 
Diabetic mouse models can provide data on how sensory axons are able to regenerate and 
sprout following a treatment intending to enhance axonal regeneration as sensory nerves 
are typically more severely impacted. 
 
Amyotrophic Lateral Sclerosis 
Amyotrophic lateral sclerosis (ALS) is characterized by a progressive loss of 
motor neurons, eventually leading to muscle wasting and finally death (127). While there 
are both sporadic and familial forms of ALS, there is very little known about the actual 
causes of the disease. Despite this, many mutations have been discovered to be associated 
with familial forms of ALS. One mutation, the glycine 93 to alanine point mutation in the 
superoxide dismutase 1 gene (SOD1) (128), has proven to be a useful manipulation for 
generating a popular mouse model of ALS by highly expressing the mutant SOD1G93A 
gene (129, 130). There have been many studies done on this mouse model to characterize 
the progression of the disease within the mouse. The earliest signs of disease begin to 
show up at around P45 and manifest as a significant decline in the number of innervated 
neuromuscular junctions (NMJs) (88, 131-135). This early denervation can also be 
detected as a decline in the amplitude of the compound muscle action potential (CMAP) 
using electrophysiological analysis (131, 135). It is only later, around 90 days, that 
clinical symptoms begin to appear and degeneration becomes evident in the ventral roots 
and motor neuron cell bodies (88, 131-135). This early peripheral nerve degeneration 
preceding abnormal motor neuron morphology was also identified in an ALS patient who 




Studies have shown that type IIb, fast-fatigable motor fibers have a selective 
vulnerability for degeneration in the SOD1G93A mouse compared with the type I or IIa 
subtypes (88, 134, 136, 137). It is also well known that the largest motor neurons die 
first, pointing toward an inability to keep up with a high metabolic demand (135, 137). 
Despite this, there have not been any extensive studies done on very long nerves of a 
single-nerve type within the SOD1 mouse. This is most likely due to the limitations set 
by using the sciatic nerve and its muscles to study the degeneration profile in these mice. 
As outlined in the previous section, utilizing the LTN-CMM system as a means of 
studying this length dependent degeneration may be an attractive alternative. 
In order to accurately investigate the earliest signs of degeneration of the type II 
motor fibers, one must take into account the variations brought on by different genetic 
backgrounds. The B6SJL mixed background SOD1 mouse model, used in the studies 
mentioned earlier, present with overt clinical symptoms around P90 with a life span of 
around 130 days (86, 131, 132, 135, 138). In contrast, mice with the C57BL/6J 
background have a delayed disease onset of around 110 days and an extended life span of 
approximately 150 days (129, 138-141). The mice on the B6 background show an 
extended preclinical phase which provides a longer window to study the early stages of 
disease before the onset of clinical symptoms and to investigate potential therapeutics for 
enhancing muscle reinnervation. In addition to the B6 mice having a longer progression, 
there is also a mouse model which have a low copy number of mutant SOD1G93A (B6.Cg-
Tg(SOD1*G93A)dl1Gur/J) which have a disease onset around 200 days (142) and die 




Despite the ongoing degeneration in SOD1 mice, there is some extent of axonal 
sprouting from the surviving axons in an attempt to reinnervate the vacated NMJs. This is 
evident by an observed increase in the size of the motor units and some sparse 
reinnervation seen morphologically in the SOD1 mice (87, 132, 133). While this partial 
reinnervation may be useful in the early phase of the disease, as the motor units increase 
in size, so does the metabolic demand. This eventually catches up with the surviving 
axons and they can no longer support the increased motor unit size which, ultimately 
leads to the later phase of rapid decline (131). Another obstacle for regeneration, as 
mentioned above, is that the type II fast-fatigable fibers are fairly resistant to regeneration 
and do not sprout easily (88). 
 
Problems in peripheral nerve regeneration 
Peripheral nerves must overcome many obstacles for proper regeneration  
The ability for regeneration in the PNS is especially important since peripheral 
nerves are less protected than those in the CNS and are injured much more frequently. 
While the peripheral nervous system contains the capacity for regeneration, it is often 
slow and incomplete, leading to less than favorable outcomes following severe nerve 
trauma (see Figure 4) (9, 27, 28). This is especially true in humans where the average rate 
of regeneration is around 2-5mm per day (145). Depending on the site of injury and how 
far away it is from the target muscle, the regeneration rate may be too slow for the axon 
to reach the muscle before other changes begin to happen that are detrimental to 
regeneration (146, 147). When a muscle is denervated for too long, the neuromuscular 




axon’s ability to reinnervate its target muscle (148). In addition to the breakdown of 
NMJs, supporting Schwann cells also become unable to aid regenerating axons due to 
gene downregulation and a reduced number of Schwann cells (149). All of these changes 
contribute to significantly limit the effectiveness of peripheral nerve regeneration and can 
lead to suboptimal clinical outcomes. Additionally, axonal regeneration is very inefficient 
and many of the axonal sprouts that are sent out never end up reaching their target. 
Another major setback is that even when the axon is able to reach its target, the 
myelination and ability of the nerve to fire correctly remains impaired, even long after the 






   
Fig. 4. Problems in peripheral nerve regeneration.  
There are many ways axons of the PNS can get injured either by nerve trauma, various peripheral 
neuropathies, or the early stages of motor neuron diseases. The injuries that arise from these 
events leads to axonal damage and denervation. In order for regeneration to occur, many 
obstacles, which are detailed in the regeneration obstacles box, need to be overcome. With the 
current intervention of surgical repair and the basal state of regeneration, the extent of 
reinnervation is typically only partially complete. With the development of novel treatments, we 
hope that complete reinnervation can be achieved. In cases of severe trauma with no surgical 





Peripheral nerve regeneration is further impaired by age and disease 
 These issues are even greater when the repair process itself becomes reduced, 
either due to aging, neurodegenerative disorders, or peripheral neuropathies (87, 88, 122, 
151). In terms of aging, the rate and number of regenerating axons in elderly patients and 
animals are significantly reduced following a peripheral nerve injury (151). All of the key 
steps in peripheral nerve regeneration are reduced in aged rats. The peripheral nerves do 
not sprout as extensively, myelin debris clearance is delayed and impaired, and Schwann 
cell activation is inhibited (14, 87, 151). In cases of peripheral neuropathies or motor 
neuron diseases with distal axonal degeneration, such as the three diseases discussed 
previously, the rate of axonal regeneration may be overwhelmed by the rate of axonal 
degeneration occurring via the disease process (86-88, 122, 135). This is further 
complicated by subsequent neuronal cell loss in ALS which reduces the number of 
available axons for regenerating. This then increases the burden on the surviving axons to 
generate axonal sprouts and increases their motor unit size. 
 
Therapeutic options for enhancing axonal regeneration are absent 
 Despite insufficient repair following axonal insult to the peripheral nervous 
system, either due to trauma or disease, there are currently no therapeutics available to 
enhance regeneration. As it stands right now, the best available treatment is the surgical 
reattachment of the distal portion of the nerve to the proximal stump in hopes that the 
proximal stump can sprout into the vacated Schwann cell tubes to accelerate repair (29). 
Even with the best surgical techniques however, this still leaves many without full 




which improve the connection between the proximal and distal stumps (152). 
Unfortunately, this approach doesn’t aid those who suffer from severely pinched nerves 
or those suffering from neurodegenerative diseases, nor does it address the slow rate of 
axonal growth. Other potential therapeutics have looked into electrically stimulating the 
nerves to enhance regeneration. Some research has shown that when the proximal portion 
of an injured nerve is stimulated, axonal growth is enhanced (13, 153). However, this 
strategy has the potential to be an invasive and painful experience for the patient. What is 
truly needed is a minimally invasive therapy, such as a small molecule drug, that can be 
administered following successful reattachment which can accelerate the growth rate. 
 
Beta secretase as a novel regulator of peripheral nerve regeneration 
Reduced BACE1 activity levels improve peripheral nerve regeneration 
Our lab has identified a novel role for BACE1 in modulating peripheral nerve 
regeneration following injury. Based on our data, we have determined that BACE1 
activity levels have a negative effect on the efficacy of peripheral nerve regeneration. We 
observed a significant improvement in peripheral nerve regeneration following a sciatic 
nerve crush in BACE1 KO mice when compared with their WT littermates (25). The 
nerves in the KO mice were able to grow further, on top of having a greater number of 
regenerated axons compared with WT mice. There was also an improvement in muscle 
reinnervation in the BACE1 KO mice. These experiments provided interesting data 
highlighting a novel role for BACE1 in regulating peripheral nerve regeneration. 
However, these experiments did not narrow down where BACE1 was exerting its effects. 




themselves, enhanced macrophage recruitment and activity, or even enhanced Schwann 
cell activation and axonal support.  
While BACE1 activity’s influence over the neuronal component of peripheral 
nerve regeneration is an interesting piece of the puzzle, we also need to investigate the 
role that macrophage and Schwann cell BACE1 activity levels play in enhancing 
regeneration. Our study using global BACE1 KO mice indicated that macrophages are 
not only recruited in greater numbers, but also engulf more myelin debris following a 
peripheral nerve injury (25). We also observed an increased expression of tumor necrosis 
factor receptor 1 (TNFR1), a macrophage signaling receptor, in the distal stump of the 
injured nerve in both BACE1 KO mice and WT mice treated with a BACE1 inhibitor 
(24). While this data indicates that macrophages are influenced with reduced BACE1 
activity, it does not determine whether this is due to BACE1 activity within the 
macrophages themselves or in the cells that the macrophages interact with. Data 
investigating how BACE1 activity levels influence the initial activation of Schwann cells 
following peripheral nerve injuries has not yet been studied. However, there is evidence 
which indicates that BACE1 activity is involved in peripheral nerve remyelination 
following axonal outgrowth and is important for proper remyelination to occur (54, 154). 
More studies need to be conducted investigating the role of BACE1 activity solely in the 
neurons, Schwann cells, and macrophages. 
 
BACE1 substrates themselves influence axonal regeneration 
 In addition to our own data, there has been some evidence that some of the 




studies have found that the processing of APP itself has an effect on neurite outgrowth. 
Knocking out APP in cultured neurons has led to enhanced neurite outgrowth (155, 156), 
while soluble APP has been shown to have an inhibiting effect on neurite outgrowth 
(157). While interesting, the effects APP processing has on peripheral nerve regeneration 
has been inconclusive thus far. The processing of another BACE1 substrate, NCAM, has 
also been shown to have an impact on neurite outgrowth and branching. The cleavage of 
NCAM leads to the shedding of an ectodomain and reduces neurite outgrowth, which can 
be rescued by preventing the release of the ectodomain (158). Additionally, the cleavage 
of CHL1 by BACE1 also impacts neurite outgrowth. When the release of CHL1’s 
cleavage product is prevented, the growth cone no longer collapses and promotes neurite 
extension (159). Taken together with our own data, we hypothesize that BACE1 activity 
on its various substrates plays an important role in regulating peripheral nerve 







Fig. 5. Potential mechanism for how BACE1 activity levels regulate peripheral axon growth.  
Since adhesion molecules are essential for proper axonal outgrowth and interaction with Schwann 
cells (depicted in blue), I hypothesize that BACE1 regulates peripheral axonal outgrowth by 
modulating the cell surface expression levels of various adhesion molecules, such as CHL1 and 
L1. In WT mice, adhesion molecules are moderately expressed on the cell surface leading to 
basal regeneration rates. With reduced BACE1 expression, as in KO mice, adhesion molecules 
aren’t cleaved and therefore remain at the cell surface in greater numbers, enhancing interactions 
with Schwann cells and leading to increased growth. When BACE1 is overexpressed, there is 
more cleavage causing fewer adhesion molecules to be expressed on the cell surface, impairing 







Beta secretase inhibitors as a potential therapeutic strategy for 
enhancing peripheral nerve regeneration 
BACE1 inhibitor development 
 BACE1’s important role as one of the two enzymes needed to generate A 
plaques in AD has led to a robust interest in the development of BACE1 inhibitors in the 
hopes that reducing the A burden may improve AD symptoms. Early efforts to develop 
a BACE1 inhibitor took advantage of a peptide molecule that was unable to be cleaved 
by BACE1, however, this molecule lacked the ability to cross the blood-brain-barrier and 
was not orally bioavailable (160). Due to this difficulty, researchers began to focus on 
developing small molecule inhibitors in the hopes that they would improve the desired 
pharmacological characteristics. Early generations of small molecule BACE1 inhibitors 
indeed had better cell membrane permeability and good target engagement, but 
unfortunately there were still issues with generating a high enough concentration in the 
brain, as well as some toxicity issues with retinal degeneration and abnormal liver 
biochemistry, which were thought to be related to off-target effects and not BACE1 
inhibition itself  (160-163). The most recent generation of BACE1 inhibitors are now able 
to enter the brain at high enough concentrations to achieve robust reductions in A levels 
in animal models, are also orally bioavailable, and early phase I trials show no severe 
toxicity issues (42, 45, 48, 160, 164). Due to this vast improvement, many companies 
have begun clinical trials of their BACE1 inhibitors and we now have a large pool of data 





BACE1 inhibitors developed for AD have good safety profiles 
 As mentioned earlier in this introduction, because BACE1 has a large role in 
generating A plaques in AD, many pharmaceutical companies have made great efforts 
to develop small molecule BACE1 inhibitors. Early efforts were held back due a lack of 
small molecules that could penetrate the blood-brain-barrier as well as toxicity issues, 
such as the liver toxicity seen with the Eli Lilly BACE1 inhibitor LY2886721 during 
their phase 2 trials (160). This led many to speculate whether BACE1 inhibitors were a 
feasible target for AD. However, recent advances in the development of these drugs has 
shown more promise. Recently, Merck announced that their latest BACE1 inhibitor, 
verubecestat (MK-8931), was well tolerated at various doses in patients enrolled in their 
phase I clinical trial (42). Verubecestat also showed a robust decrease in CSF A 
production, indicative of proper target engagement. In addition to verubecestat, 
AstraZeneca/Lilly also have a promising small molecule BACE1 inhibitor, AZD3293, 
currently in phase II/III clinical trials. This drug was also well tolerated in phase I trials 
and showed a marked decrease in CSF A production (48). 
 Unfortunately, Merck recently stopped their mild/moderate Phase III trial for 
verubecestat due to a lack of significant clinical changes observed. Despite being a 
disappointing setback, this result was unsurprising to those in the field as A levels tend 
to plateau and neuronal death is widespread by the time clinical symptoms begin to 
appear. While this is bad news for AD, all may not be lost for those who have sunk 
billions into developing BACE1 inhibitors. Since high BACE1 activity appears to have a 
negative impact on peripheral nerve regeneration, we hypothesize that BACE1 inhibitors 




regeneration. Indeed, when we administered an older BACE1 inhibitor, BACE1 inhibitor 
IV, for 7 days following a sciatic nerve crush, we observed an apparent increase in 
regenerated axons as well as enhanced axonal debris clearance (25). This is a promising 
start for determining whether BACE1 inhibitors may find a new life as peripheral nerve 
regeneration enhancers. 
 In addition to the generation of safe, well-tolerated BACE1 inhibitors, treating 
peripheral nerve injuries with small molecule inhibitors may not be impacted by the 
blood-brain barrier issues that hinders CNS drug development. Unlike the blood-brain 
barrier, the nerve-blood barrier is rather leaky and would most likely allow larger 
molecules through at lower concentrations (165). This may be beneficial and could 
potentially allow for the development of more potent BACE1 inhibitors that is unable to 
cross the blood-brain barrier, may be able to cross the nerve-blood barrier. Additionally, 
being able to get a high efficiency in nerves with a lower dose would also lower the risk 
of toxicity issues that has been seen with some BACE1 inhibitors at higher doses and 
would give a therapeutic advantage to treating peripheral nerve injuries with BACE1 
inhibitors. 
 
Potential issues surrounding the use of BACE1 inhibitors following acute peripheral 
nerve injuries 
 While utilizing BACE1 inhibitors as a means to enhance regeneration following a 
peripheral nerve injury has promise, due to BACE1’s promiscuous nature, potential 
issues of inhibition need to be closely monitored. This especially concerning as the 




(42, 48) and may lead to unintended side effects where chronic BACE1 inhibition in 
other tissues may alter the processing of any of its other substrates. Firstly, because 
BACE1’s cleavage of NRG1 type III is involved in the myelination of peripheral nerves, 
it is important to think about how this may negatively impact peripheral nerve 
remyelination as well as the existing myelin on uninjured axons. In the case of uninjured 
nerves, their myelination does not appear to be altered with BACE1 inhibition as we have 
seen in our own lab (unpublished data) as well as by other groups (46). For regenerating 
axons, remyelination would most likely be reduced for as long as BACE1 activity is 
being inhibited. This hypomyelination would impact the ability of the axons to fire in a 
coherent manner and may have a negative impact on the effectiveness of the regenerated 
axons to engage with their targets correctly. How large this deficit would be is a factor 
that needs to be studied with regards to administering BACE1 inhibitors following a 
peripheral nerve injury. While this deficit could be similar to the hypo-remyelination 
observed in BACE1 KO mice (54, 154), it may be ameliorated by only administering the 
BACE1 inhibitors for a short time period, a couple of weeks at most, immediately 
following the injury. This dosage schedule would induce increased axonal outgrowth 
during the early stages of repair and once the inhibition of BACE1 is abolished, 
remyelination would be allowed to occur in a normal capacity and would hopefully allow 
for proper axonal firing to occur. Additionally, there is some evidence that BACE1 
cleavage of NRG1 type III is not essential for the induction of myelination (55).  
 Another issue that could potentially arise when using BACE1 inhibitors is that 
there may be possible defects with the muscle spindles. In the absence of BACE1, mice 




BACE1 was inhibited in adult mice, Cheret et al. (166) found that muscle spindle 
maintenance was impaired, as was motor coordination. While this finding may be 
troubling for the use of BACE1 inhibitors, phase I clinical trial reports about adverse 
responses to BACE1 administration in human patients did not report any issues with 
motor coordination, even at the highest doses administered (42). This difference in 
adverse effects may be a result of species specific effects of BACE1 inhibition as a 
difference in behavioral studies and post-natal mortality were reported between knockout 
mice and rats (167). The lack of issues seen in human patients following BACE1 
inhibitor treatment lead us to believe that many of the issues surrounding possible pitfalls 
associated with BACE1 inhibition may not be as severe as originally thought. 
 In addition to issues with inhibiting BACE1 itself, it is also possible that these 
compounds may inhibit other aspartyl proteases leading to off-target effects. Since 
BACE2’s structure is extremely similar to BACE1, the BACE1 inhibitors currently in 
clinical trials usually have as strong of an affinity for BACE2 as they do BACE1 (164, 
168). Fortunately, when these drugs were reported on following phase I clinical trials no 
significant adverse effects were reported in human patients (42, 48). Another concern is 
that these drugs may inhibit Cathepsin D, another aspartyl protease responsible for 
degradation and activation of various proteins in the lysozyme. Despite the similarities 
between BACE1 and Cathepsin D, the current generation of BACE1 inhibitors are not 







BACE1 inhibitor treatment may avoid axonal guidance issues in adults 
 BACE1 inhibitors being used to enhance peripheral nerve regeneration may also 
be able to overcome many of the axonal guidance issues that have been identified. Many 
of these studies were performed in null mice, either of BACE1 or its substrates, and using 
an inhibitor that would not completely abolish BACE1 activity levels may lead to a less 
severe phenotype with regards to axonal guidance. Additionally, these studies were also 
focusing on how a loss of BACE1, or its substrates affects axonal guidance in the 
developing CNS. Due to the wide variety of BACE1 substrates, it may be possible that 
the substrates involved in impaired axonal guidance in the CNS may not be as important 
for similar functions in the peripheral nervous system. An alternative hypothesis is that 
these substrates may interact with different molecules and cells in the periphery which 
lead to a different phenotype. This makes sense, as axons in the CNS interact with 
oligodendrocytes and astrocytes while the PNS axons interact with Schwann cells. 
Indeed, our lab has not noticed any morphological differences in how NMJs are 
innervated in uninjured BACE1 KO mice. Another major issue to note with these studies 
is that many of the null studies may be related to developmental defects, as the mice are 
lacking BACE1 and its substrates from the beginning. In the developing mouse, many 
neuronal connections are being made, both in the CNS and PNS. Due to this high 
activity, a lack of BACE1 early on may be more detrimental than later in development. 
Using BACE1 inhibitors for the treatment of peripheral nerve injuries would occur after 
the bulk of the synaptic connections had been formed and would not effect a majority of 
the synapses formed in the adult. In addition to the adult nervous system being less 




there would not need to be a very prolonged treatment and would allow proper guidance 
to occur in normal pruning. Both of these factors could potentially avoid any of the 
guidance issues observed in the BACE1 KO mice and would support the use of BACE1 
inhibitors in adults. 
 
BACE1 inhibitors may be useful in early stage peripheral neurodegenerative diseases 
 We also hypothesize that in addition to peripheral nerve injuries, these inhibitors 
may be helpful in the early stages of peripheral neurodegenerative disorders. In the 
earliest stages of motor neuron disease, axonal degeneration typically precedes neuronal 
cell body death (88, 131-135). The axons of these neurons also die back at different rates 
depending on their susceptibility to degeneration based on multiple factors such as fiber 
type, size, and length (88, 134-137, 169). We theorize that motor function, and therefore 
quality of life, may be prolonged in the early stages of these diseases if the surviving 
motor neurons could be encouraged to sprout and regrow in an attempt to reinnervate 
denervated muscle. It is true that even with a disease background, peripheral nerves do 
have the capacity to sprout, however limited it may be (85, 87, 170, 171). If the rate of 
axonal sprouting and outgrowth can be enhanced using a BACE1 inhibitor, it may be able 
to keep up with the rate of degeneration for a time, especially in slowly progressing 
disorders. 
 
Concluding remarks of the introduction 
 Our current understanding of how BACE1 is involved in regulating axonal 




interesting relationship between BACE1 activity levels and how effective axons are at 
regenerating following an acute nerve injury. Our own data has determined that reducing 
BACE1 activity levels improves axonal regeneration, but whether the inverse is true still 
remains to be understood. Additionally, we are still unclear as to which cells involved in 
peripheral nerve regeneration BACE1 activity levels are working on. Despite these gaps 
in knowledge, our original finding has interesting clinical implications. If the 
administration of BACE1 inhibitors following an acute nerve injury can help to increase 
the rate and efficacy of peripheral nerve regeneration, it would fill a much-needed 
therapeutic gap for acute nerve injuries. Additionally, BACE1 inhibitors may also be 
useful in the early stages of peripheral neuropathies as a means for enhancing the rate of 
axonal regeneration, which may be able to compensate for the progressive loss of axons 
and lead to prolonged function. 
 This dissertation sets out to answer 3 major questions related to how BACE1 
activity levels influence peripheral nerve regeneration and how we can utilize this 
knowledge to develop potential therapeutics:  
1) Does BACE1 overexpression, in neurons, lead to impaired axonal regeneration?  
2) Can BACE1 inhibitors enhance peripheral nerve regeneration and axonal sprouting 
following acute nerve injuries?  
3) Are BACE1 inhibitors able to improve early regeneration in the SOD1G93A mouse 







Chapter 2: Overexpression of BACE1 leads to reduced 
peripheral nerve regeneration after acute nerve injury 
Introduction to chapter 2 
 Before exploring how BACE1 activity levels can be manipulated 
pharmacologically as a potential therapeutic, we first wanted to further characterize how 
BACE1 activity is able to regulate peripheral nerve regeneration in response to a nerve 
injury. Our original data determined that a complete loss of BACE1 in all the components 
of the peripheral nerve regeneration machinery, namely the neurons, Schwann cells, and 
macrophages, led to an increase in peripheral nerve regeneration and enhanced axonal 
debris clearance and phagocytosis by macrophages (25, 172). While a promising first 
step, these studies do not address the question of whether the reverse is true. It also does 
not provide any information on the individual roles of BACE1 activity in the neurons, 
Schwann cells, and macrophages. In order to tackle some of these missing links, we 
carried out sciatic nerve crush experiments in mice that were engineered to overexpress 
human BACE1 under the neuronal specific Thy1.2 promoter generated from a modified 
Thy1 expression cassette which is expressed only in neurons and not in non-neuronal 
cells, such as the Schwann cells (44, 173). These mice were originally designed to study 
high BACE1 activity levels in AD and therefore there is very little information about 
potential phenotypes beyond enhanced APP processing and how it leads to altered Aβ 
deposition and neurodegeneration in the brain (43, 44). 
 In this chapter, we set out to characterize the normal peripheral axonal 




of BACE1 and how it affects peripheral nerve regeneration following axonal injury. We 
then determined how these nerves degenerated and regenerated following a sciatic nerve 
crush injury and whether our initial hypothesis that BACE1 activity levels inversely 
influence peripheral nerve regeneration holds true with increased BACE1 activity levels.  
 
Results 
The following data was published in C. Tallon, E. Rockenstein, E. Masliah, M. H. Farah, 
Increased BACE1 activity inhibits peripheral nerve regeneration after injury. Neurobiol Dis 106, 
147-157 (2017). 
 
Overexpression of BACE1 does not alter uninjured axon morphology or physiology 
Previous studies suggest that BACE1 activity levels influence the extent of 
peripheral nerve regeneration (25, 26, 172). A testable prediction of this postulate is that 
an increased expression of BACE1 would be expected to impede nerve regeneration. In 
order to investigate whether increased BACE1 expression reduces nerve regeneration, 
We used transgenic (Tg) mice where human BACE1 was driven by the Thy-1 promoter 
and has been shown to express BACE1 in neurons (44). These BACE1 Tg mice have 
been investigated in the field of Alzheimer's disease, but not in peripheral nerve studies 
(44, 174). Therefore, we first evaluated the sciatic nerves of the BACE1 Tg mice before 
injury and observed a marked increase in BACE1 expression in both the sciatic nerve and 
brain of the BACE1 Tg mice (Fig. 6A; WT n = 5; Tg n = 5). Morphologically, the sciatic 
nerves of both WT (Fig. 6B) and BACE1 Tg (Fig. 6C) mice were indistinguishable from 




of axons in the sciatic nerve. We did not observe any difference in the amplitude of the 
CMAP recorded in the muscles of the footpad between WT (n = 15) or Tg (n = 19) mice 
with either ankle stimulation (WT = 19.22 ± 2.18 ms, Tg = 19.38 ± 1.55 ms; p = 0.951) 
or hip stimulation (WT = 13.42 ± 1.91 ms, Tg = 13.73 ± 1.04 ms; p = 0.883) (Fig. 6D). 
There was also no latency difference between WT or Tg mice with ankle stimulation 
(WT = 0.717 ± 0.103 ms, Tg = 0.886 ± 0.111 ms; p = 0.414) or hip stimulation 
(WT = 1.454 ± 0.128 ms, Tg = 1.554 ± 0.0982 ms; p = 0.534) (Fig. 6E). Both of these 
electrophysiological parameters support there being no difference in axon number and 
extent of myelination. Taken together, these data indicate that BACE1 overexpression 
does not affect the normal morphology or physiology of the uninjured sciatic nerve, 
allowing us to investigate the effect of BACE1 overexpression on nerve regeneration in 











Fig. 6. BACE1 overexpression does not affect nerve morphology and electrophysiology.  
A) Western blot showing BACE1 overexpression in both the sciatic nerve and the brain of 
transgenic mice (Tg). B–C) Cross section of a WT (B) and Tg (C) sciatic nerve stained with 
toluidine blue. Both mice have normal axonal myelination. Scale bar represents 20 μm. D) The 
amplitude of the CMAP recorded at the foot was not altered between the WT (blue, n = 15) and 
Tg (red, n = 19) mice when the uncrushed sciatic nerve was stimulated at either the hip or the 
ankle. E) The latency of the CMAP was not altered in the Tg mice with either stimulation at the 
hip or ankle (WT n = 15, Tg n = 19). Bars represent mean ± standard error. C. Tallon, E. 
Rockenstein, E. Masliah, M. H. Farah, Increased BACE1 activity inhibits peripheral nerve 








BACE1 overexpression does not alter axonal degeneration and debris clearance after 
injury 
While uninjured WT and BACE1 Tg nerves are electrophysiologically and 
morphologically similar, it is possible that increased neuronal expression of BACE1 
might affect axonal degeneration and debris clearance following nerve injury since 
BACE1 KO mice have enhanced debris clearance and macrophage recruitment. We 
therefore examined myelin debris and macrophage recruitment in BACE1 Tg and WT 
mice after injury. We performed a complete sciatic nerve transection in WT (n = 4) and 
Tg (n = 3) littermates, collected the distal nerve segments and stained for myelin basic 
protein (MBP) and CD68, a macrophage marker. There was no observable difference 
between the amount of myelin debris nor the distribution of the debris (Fig. 7 C and D). 
There was also no observable difference between the number of macrophages present in 
WT or Tg mice, either before or after injury (Fig. 7 E–H). Quantifying the number of 
macrophages present after injury confirmed that there was no significant difference in the 
density of macrophages between the WT and Tg mice (Fig. 7 I, WT = 107,612 ± 16,371 
macrophages/mm3 and Tg = 96,218 ± 2287 macrophages/mm3, p = 0.529). These results 
indicate that exclusively overexpressing BACE1 in neurons does not alter axonal 









Fig. 7. BACE1 overexpression does not alter degeneration 5 days after complete sciatic 
nerve transection.  
A–D) Longitudinal sections of sciatic nerves stained for myelin basic protein. Scale bar 
represents 50 μm. A–B) Uninjured nerves from WT (A) and Tg (B) mice showing similar levels 
of myelination. C-D) Injured nerves from WT (C) and Tg (D) mice where the extent of 
degeneration was indistinguishable between genotypes. E-H) Longitudinal sections of sciatic 
nerves stained for macrophages with CD68. Scale bar represents 20 μm. E–F) Uninjured nerves 
from WT (E) and Tg (F) mice with very few macrophages present. G–H) Representative images 
of comparable macrophage influx between WT (G) and Tg (H) mice. I) Quantification of the 
volumetric density of macrophages in WT (n = 4) and Tg (n = 3) distal sciatic nerve stumps with 
no difference between WT and overexpressing mice. Bars represent mean ± standard error. C. 
Tallon, E. Rockenstein, E. Masliah, M. H. Farah, Increased BACE1 activity inhibits peripheral 





The data presented in Figs. 6 and 7 collectively indicated that BACE1 
overexpression does not affect the normal morphology or physiology of the uninjured 
sciatic nerve nor does the nerve degeneration profile differ between BACE1 Tg and WT 
injured nerves. Thus, we proceeded to investigate the effect of neuronal BACE1 




BACE1 overexpression impairs axonal regeneration as early as 3 days after injury 
We first determined whether the initial outgrowth of regenerating axons was 
altered in the injured nerves of BACE1 Tg mice. We stained the nerves of 3 WT and 3 
BACE1 Tg mice for GAP43 expression, a regeneration associated gene, and measured 
the extent of axonal outgrowth 3 days after a sciatic nerve crush. In uninjured nerves, no 
detectable GAP43 staining was present under our staining protocol (Figs. 8A and B). 
However, in the injured nerves, high levels of GAP43 staining was present near the crush 
site and extended distally, indicating the beginning of axonal regeneration (Fig. 8C and 
D). We measured the level of axonal outgrowth by measuring the length of the longest 
GAP43 positive axon from the crush site and found that there was a significant reduction 
in the length of the longest axon in the BACE1 Tg mice (Fig. 8 C–E). On average, WT 
axons regenerated 5.17 ± 0.368 mm while the transgenic mice only grew 
2.86 ± 0.262 mm (p = 0.00695) 3 days after being crushed. We also observed a marked 
reduction in another early axonal regeneration marker, SCG10. Transgenic mice had a 
drastic reduction in staining while the WT mice had extensive staining distal to the crush 
site (Fig. 9A and B). We therefore conclude that overexpressing BACE1 reduces the 










Fig. 8. BACE1 overexpressing mice have reduced early regeneration 3 days after a sciatic 
nerve crush.  
A–B) Longitudinal sections from uninjured sciatic nerves of WT (A) and Tg (B) mice with very 
little GAP43 staining. C–D) Representative longitudinal sections from WT (C) and Tg (D) 
injured sciatic nerves. The crush site was located at the left of the image (white arrow) and the red 
arrows indicate the longest GAP43 positive axons. WT mice have more extensive GAP43 
staining and longer axons when compared to Tg littermates. E) Quantification of the length of the 
longest GAP43 positive axons in WT (n = 3) and Tg (n = 3) mice. Tg mice have a 40% reduction 
in the length of the longest axon compared with WT littermates. * indicates p < 0.05. Bars 
represent mean ± standard error. Scale bar represents 500 μm. C. Tallon, E. Rockenstein, E. 
Masliah, M. H. Farah, Increased BACE1 activity inhibits peripheral nerve regeneration after 














Fig. 9. Fewer axons extend distally from the crush site in BACE1 transgenic mice 3 days 
following injury.  
A) Representative longitudinal section of a WT sciatic nerve stained with SCG10 antibody with 
extensive neurite outgrowth. B) Representative longitudinal section of a BACE1 transgenic 
sciatic nerve stained with SCG10 antibody where there are only a few axons growing out from 
the crush site. In both images the crush site is to the left. C. Tallon, E. Rockenstein, E. Masliah, 
M. H. Farah, Increased BACE1 activity inhibits peripheral nerve regeneration after injury. 
Neurobiol Dis 106, 147-157 (2017). 
 
Overexpressing BACE1 leads to impaired axonal regeneration 10 days after injury 
We next asked whether regeneration is impaired in BACE1 Tg mice at later time 
points. We analyzed distal segments of the sciatic nerves for axonal regeneration from 6 
WT and 6 Tg mice 10 days after being crushed. BACE1 Tg crushed nerves had visually 
fewer regenerated myelinated axons compared to controls (Fig. 10A–D). The number of 
regenerated axons in BACE1 Tg mice was significantly decreased 10 days after 
performing a sciatic nerve crush when compared with WT mice (Fig. 10E; p = 0.0035). 




littermates had only 653.00 ± 86.15 regenerated axons. We also observed a drastic 
difference in neurofilament (NF) staining of sciatic nerves cross-sectioned 15 days after 
performing a sciatic nerve crush, when most of the debris had been cleared. WT sciatic 
nerves had a lot of characteristic punctate axonal staining (Fig. 11A), while Tg mice had 
almost no punctate NF staining (Fig. 11B). Based on these findings, we conclude that 
overexpressing BACE1 leads to a reduction in the ability of axons to regenerate. 
 
Fig. 10. BACE1 overexpression hinders axonal regeneration 10 days after sciatic nerve 
crush.  
A-B) Representative cross-section images of sciatic nerves from WT (A) and Tg (B) mice 
10 days post sciatic nerve crush illustrating a greater number of myelinated axons in the WT 
mice. The red arrows indicate regenerated axons. The yellow arrowheads indicate degenerated 
axons. Scale bar represents 20 μm. C–D) Representative cross-section EM images from WT (C) 
and Tg (D) mice again showing greater regenerated axons in the WT mouse. Scale bar represents 
2 μm. E) Quantification of the number of regenerated axons in WT (n = 6) and Tg (n = 6) mice. 
The Tg mice show a drastically reduced number of regenerated axons 10 days after sciatic nerve 
crush. Bars represent the mean ± standard error. * indicates p < 0.05. C. Tallon, E. Rockenstein, 
E. Masliah, M. H. Farah, Increased BACE1 activity inhibits peripheral nerve regeneration after 










Fig. 11. Neurofilament staining with BACE1 overexpression is reduced 15 days following a 
sciatic nerve crush.  
A) Cross-section of a WT sciatic nerve with small, punctate NF staining indicating regenerated 
axons have begun to repopulate the sciatic nerve. B) Cross-section of a BACE1 transgenic sciatic 
nerve with almost no punctate NF staining indicating very little regeneration has occurred. C. 
Tallon, E. Rockenstein, E. Masliah, M. H. Farah, Increased BACE1 activity inhibits peripheral 
nerve regeneration after injury. Neurobiol Dis 106, 147-157 (2017). 
 
BACE1 overexpression reduces reinnervation of the gastrocnemius muscle 15 days 
after injury 
We next determined whether the impaired regeneration seen in the BACE1 Tg 
crushed sciatic nerves was reflected by the extent of innervation of the gastrocnemius 
muscle. We collected the gastrocnemius muscles from 3 WT and 4 Tg mice 15 days after 
performing a sciatic nerve crush. Both a partial and complete overlap of the NF/SV2 




no overlap was scored as denervated. While the uninjured side showed no difference in 
innervation between WT (Fig. 12A) or Tg (Fig. 12B) mice, the injured Tg gastrocnemius 
muscles (Fig. 12D) had a reduced number of innervated NMJs when compared with their 
WT littermates (Fig. 12C). The quantification of the percentage of innervated NMJs is 
shown in Fig. 12E where BACE1 Tg mice showed 45.3 ± 7.6% innervation (n = 300 
NMJs), while the WT littermates had 67.8 ± 2.8% of their NMJs innervated (n = 239 
NMJs) (p = 0.0491). Thus, impaired axonal regeneration in the BACE1 Tg mice led to 
reduced reinnervation of the gastrocnemius muscle 15 days after injury. 
 
Fig. 12. BACE1 overexpression reduces NMJ reinnervation in the gastrocnemius muscle 
15 days after sciatic nerve crush.  
A–D) Sectioned gastrocnemius muscles stained with neurofilament and SV2 (both green) as well 
as α-BTX (red) to identify innervated and denervated NMJs. Scale bar represents 100 μm. A–B) 
Representative images of gastrocnemius muscles from uninjured sciatic nerves of both WT (A) 
and Tg (B) mice with complete NMJ innervation. C–D) Representative images from injured 
sciatic nerve gastrocnemius muscles of WT (C) and Tg (D) mice. Tg mice have fewer innervated 
NMJs than WT littermates as illustrated by the lack of red and green staining overlap. E) 
Quantification of the percent of innervated NMJs in the gastrocnemius muscle of both the WT 
(n = 3) and Tg (n = 4) mice. 15 days after crushing the sciatic nerve, the WT mice had a 
significantly higher number of innervated NMJs. Numbers in parenthesis indicate the total 
number of NMJs counted. Bars represent the mean ± standard error. * indicates p < 0.05. C. 
Tallon, E. Rockenstein, E. Masliah, M. H. Farah, Increased BACE1 activity inhibits peripheral 








Overexpression of BACE1 causes a delay in the long-term recovery of the CMAP 
After establishing that BACE1 overexpression led to a deficit in axonal 
regeneration, as well as NMJ reinnervation, we determined whether there was a 
functional difference in the repair process between WT and Tg littermates. In order to do 
this, we recorded the CMAP in the muscles of the footpad at 2, 4, 6, and 8 weeks after 
injury as outlined in Fig. 13A. The sciatic nerve was stimulated by a short electrical 
pulse, at either the hip or ankle, on the same side as the injury. The recording electrode 
was placed in the muscles of the footpad. At the ankle stimulation site, we recorded from 
6 WT and 11 Tg mice at the 2, 4, and 6-week time points. At 8 weeks, 15 WT and 19 Tg 
mice were used. Representative traces of the CMAPs recorded at the ankle for each time 
point over the 8 weeks are shown in Fig. 13B (WT) and 13C (Tg). Figs. 13D–E show the 
quantifications of the CMAP amplitudes at the ankle (Fig. 13D) and hip (Fig. 13E) 
stimulation sites over an 8-week period of recovery after a sciatic nerve crush. At our 
earliest time point of 2 weeks post-crush, the amplitudes of the CMAPs for both the WT 
and Tg mice were negligible when stimulated at the ankle (WT mean = 0.0043 ± 0.0043; 
Tg mean = 0.0059 ± 0.0040; p = 1). The same negligible amplitudes were seen in both 
the WT and Tg mice when stimulated at the hip (WT mean = 0.0093 ± 0.0032; Tg 
mean = 0.015 ± 0.0045; p = 0.319). By 4 weeks, WT mice had a significant improvement 
in the CMAP amplitudes when compared with their Tg littermates at both the ankle 
stimulation site (WT = 8.14 ± 0.67; Tg = 0.507 ± 0.075; p = 0.001) and hip stimulation 
site (WT = 2.74 ± 0.55; Tg = 0.50 ± 0.051; p < 0.001). Again, at 6 weeks, the Tg mice 
had amplitudes that were significantly lower than their WT littermates at both the ankle 




Tg = 1.598 ± 0.207; p < 0.001) stimulation sites. It is only at 8 weeks that the Tg 
littermates began to catch up with the WT mice. At the ankle stimulation site, while the 
WT mice were still higher, the difference was no longer statistically significant 
(WT = 11.977 ± 1.132; Tg = 9.443 ± 1.073; p = 0.063). At the hip stimulation site, the Tg 
amplitudes were closer to the WT values, but they were still significantly lower 
(WT = 8.005 ± 1.011; Tg = 5.412 ± 0.720; p = 0.024). This data strongly indicates that 
BACE1 overexpression is able to greatly delay the repair process of sciatic nerves after a 
nerve crush injury. While both WT and BACE1 Tg mice showed little improvement at 
2 weeks, the CMAP amplitudes in WT mice were consistently higher than their Tg 
littermates at both the ankle and hip stimulation sites. Even at 8 weeks, the BACE1 Tg 
mice were worse off than the WT mice, indicating that this impaired regeneration is in 















Fig. 13. BACE1 overexpression leads to delayed functional recovery after a sciatic nerve 
crush.  
A) Schematic diagram indicating the crush site (red x), stimulating sites (yellow lightning bolts) 
and recording site (green needle). The hip stimulation site was performed just proximal to the 
crush site while the ankle site was located distal to the crush site. The recording electrodes were 
placed in the muscles of the foot pad. B–C) Representative CMAP traces recorded from the 
footpads of WT (B) and Tg (C) mice after ankle stimulation for each time point. By week 4, WT 
mice already began to show improved CMAP amplitudes while the Tg mice did not. It is only by 
week 8 that the Tg mice began to show any significant CMAP tracings. D–E) Quantification of 
CMAP amplitudes in WT (blue, n = 15) and Tg (red, n = 19) mice with the stimulation at the 
ankle (D) or hip (E). 2 weeks after the crush, neither the WT nor Tg mice showed any 
improvement of the CMAP amplitudes at either the ankle (D) or hip (E) stimulation sites. Again, 
at both the ankle and hip, the Tg mice had a delay in the regeneration of axons while the WT 
mice showed significantly more improvement 4 weeks after the crush. Only at week 8 did the Tg 
mice begin to catch up with their WT littermates. Points represent the mean ± standard error. * 
indicates p < 0.05. C. Tallon, E. Rockenstein, E. Masliah, M. H. Farah, Increased BACE1 activity 









Summary of chapter 2 
 In this chapter, we determined that neuronal overexpression of BACE1 does not 
have any statistically significant effects on the peripheral axon morphology in uninjured 
nerves. Additionally, we were also able to determine that macrophage recruitment and 
myelin debris clearance early on during the degeneration process was not affected by 
neuronal overexpression of BACE1, hinting that neuronal BACE1 activity levels may not 
be responsible for the macrophage recruitment and phagocytosis phenotype seen in 
BACE1 KO mice. We were also able to confirm our hypothesis that increased BACE1 
activity leads to impaired regeneration following a sciatic nerve crush injury. This 
reduced regeneration capacity was evident both morphologically, by the number of 
regenerating axons and NMJ reinnervation, as well as functionally in the recovery time of 
the amplitude of the CMAP in the foot pad muscles. 
 This data, together with our BACE1 KO studies, supports the overarching 
hypothesis that BACE1 activity levels inversely influence the efficacy of peripheral nerve 
regeneration following axonal injury. Having determined this relationship, we next 
investigated whether we could apply this new understanding as a potential therapy for 








Chapter 3: Decreased BACE1 activity enhances peripheral 
nerve regeneration following a nerve crush injury 
Introduction to chapter 3 
Due to BACE1’s role in generating A plaques in AD, many iterations of BACE1 
inhibitors have been developed over the years in the hopes of creating a drug that would 
be effective in slowing or halting the disease progression of AD. Many of the earlier 
inhibitors were plagued with issues surround difficulties penetrating the blood-brain 
barrier and various toxicity issues (160). Our lab had briefly investigated whether two 
early BACE1 inhibitors, BACE1 inhibitor IV from Calbiochem (161) and WAY 258131 
from Wyeth (175), could enhance peripheral nerve regeneration following a sciatic nerve 
crush (25). We observed an apparent enhanced debris clearance as well as increased 
axonal regeneration both in sciatic nerve cross sections and sections of the foot pad.  
While this data was encouraging, it gave a very preliminary insight into the 
potentials of using BACE1 inhibitors to enhance regeneration following a nerve injury. In 
addition to this, these experiments also used BACE1 inhibitors that never made it to 
clinical trials. In this chapter, we further explore the efficacy of BACE1 inhibition on 
enhancing peripheral nerve regeneration following a sciatic nerve crush injury using two 
more recent BACE1 inhibitors that made it to clinical trials, LY2886721 from Eli Lily 








BACE1 inhibitors target BACE1 activity 
 Before dosing the cells and animals with the BACE1 inhibitors, we first 
determined that both BACE1 inhibitors, LY2886721 and MBI-9, were able to engage 
their target and reduce BACE1 activity. One way to monitor whether or not BACE1 
activity is reduced is to determine the expression level of full length APP. Full-length 
APP typically appears as a doublet band around 110-135 kDa. We first tested whether the 
Eli Lilly BACE1 inhibitor, LY2886721, at a dose of 100mg/kg, was able to reduce 
BACE1 activity by comparing 3 vehicle treated and 3 inhibitor treated mice (Figure 14 
A-B). We saw an increase in the intensity of the band in the brain (vehicle = 
0.266±0.0767; inhibitor = 0.956±0.134; p=0.011) and sciatic nerve tissue (vehicle = 
0.103±0.0309; inhibitor = 0.502±0.104; p=0.0213) of mice treated with the LY2886721 
inhibitor (Figure 14B). We also ensured that the Merck inhibitor, MBI-9, at a dose of 
30mg/kg, was able to inhibit BACE1 activity in brain and spinal cord tissue by 
comparing 4 vehicle treated and 4 inhibitor treated mice (Figure 14 C-D). Again, we saw 
an increase in the intensity of the full-length bands in the inhibitor treated mice (Figure 
14D, brain vehicle = 0.544±0.0447; brain inhibitor = 0.8570±0.0257; brain p=0.000914; 
spinal cord vehicle = 0.116±0.0127; spinal cord inhibitor = 0.393±0.232; spinal cord 
p=0.0000434). Based on these observations we were able to conclude that both drugs 







Fig. 14. Oral BACE1 inhibitors reduce full length APP. 
A) Representative western blot bands from brain and sciatic nerve tissue showing increased full-
length APP expression following Eli Lily LY2886721 administration. B) Quantification of 
normalized full-length APP band intensity from vehicle (blue) and LY2886721 inhibitor (orange) 
treated brain and sciatic nerve tissue. Band intensity was increased in LY2886721 treated mice 
indicating that the drug was able to inhibit BACE1 activity. C) Representative blots of full-length 
APP from the brain and spinal cord of mice treated with vehicle or the Merck MBI-9 inhibitor. D) 
Quantification of the intensity of full-length APP in the brain and spinal cord of vehicle (blue) 
and MBI-9 (red) treated mice. Inhibitor treated mice had increase full-length APP indicating that 
MBI-9 was also able to effectively inhibit BACE1 activity levels. Bars represent the mean ± 














BACE1 inhibition enhances neurite branching and outgrowth in vitro 
 After ensuring that the BACE1 inhibitors were targeting BACE1, we determined 
whether inhibiting BACE1 activity was able to enhance neurite outgrowth in vitro. We 
collected DRGs from 3 WT C57BL/6J mice and plated the cells on glass coverslips. 
After allowing the cells to grow for 24h, we gave the cells either DMSO only (vehicle 
treatment) or 100nM of the LY2886721 BACE1 inhibitor (inhibitor treatment) for 2 days. 
We then imaged the cells and determined the extent of neurite outgrowth and branching 
from a total of 100 cells in each condition. Cells that received the inhibitor treatment had 
visibly more neurite outgrowth and branching than those treated with vehicle only 
(Figure 15 A and B). We quantified the number of neurite branches extending from the 
cell soma and found that the inhibitor treated cells had a significantly greater number of 
neuritic processes growing out of the cell body (Figure 15C). We also found that the 
length of the longest neurite was greater in cells treated with the inhibitor (Figure 15D). 
Additionally, there were also more branches along the length of the longest neurite in 
inhibitor treated cells (Figure 15E). Based on this data, we determined that BACE1 





Fig. 15. Cultured adult mouse neurons have enhanced neurite branching after BACE1 
inhibitor treatment. 
A-B) Representative images from cultured DRG treated with vehicle (A) or a BACE1 inhibitor 
(B) for 2 days. The inhibitor treated neuron has many more neuritic processes than the vehicle 
treated neuron. C) Quantification of the number of branches per cell soma with the inhibitor 
treatment enhanced the number of branches. D) Quantification of the length of the longest 
neurite. Inhibitor treatment increased the length of the longest neurite. E) Quantification of the 
number of branches along the longest neurite. Treatment with the BACE1 inhibitor increased the 
number of branches along the longest neurite. Bars represent the mean ± standard error. * 
indicates p < 0.05. n=100 for each treatment condition. 
 
BACE1 inhibitors do not alter normal, uninjured axon morphology 
 After determining that BACE1 inhibition was able to increase neurite outgrowth 
in cultured DRG neurons, we investigated whether BACE1 inhibitors could enhance 




inhibitor had liver toxicity issues, we decided to utilize the Merck MBI-9 inhibitor in the 
mice as it is a more clinically relevant drug that has not shown any liver toxicity issues or 
other severe side effects in patients (42).  
Before performing the injury experiments, we first verified whether MBI-9 had 
any effects on normal axon morphology and physiology. We looked at the morphology 
and electrophysiology of uninjured sciatic nerves and the morphology of the 
corresponding gastrocnemius muscle after 2 weeks of inhibitor treatment. When we 
imaged cross-sections of the uninjured sciatic nerves from both vehicle or inhibitor 
treated mice, we did not observe any obvious differences between the extent of 
myelination nor the size or abundance of healthy axons (Figure 16 A and B). We also did 
not observe any difference in the innervation of the uninjured gastrocnemius muscle in 
the vehicle and inhibitor treated mice (Figure 16 C-E). The morphology of the uninjured 
NMJs and the axons innervating them did not appear to differ in shape (Figure 16 C-D). 
There was also no statistical difference in the percentage of innervated NMJs between 
vehicle and inhibitor treated mice (Figure 16E; vehicle = 99.49±0.513%, n=3; inhibitor = 
100±0%, n=3; p>0.05). There was no significant difference between the CMAP 
amplitudes of the vehicle and inhibitor treated mice (Figure 16F; vehicle = 14.915±1.541 
mV, n=12; inhibitor = 16.458±1.344 mV, n=9; p>0.457), supporting our earlier 
observation that there was no difference in the number of healthy axons present in the 
sciatic nerve. We also did not observe any difference in the latencies of the vehicle and 
inhibitor treated CMAPs which is indicative of no differences in the extent of 
myelination between the two conditions (Figure 16G; vehicle = 0.904±0.0396 s, n=12; 




BACE1 inhibitor did not alter normal axon morphology, innervation, and nerve 
physiology. 
 
Fig. 16. BACE1 inhibitors do not alter normal axon morphology and physiology. 
A-B) Cross sections of uninjured sciatic nerves in mice treated with either vehicle (A) or a 
BACE1 inhibitor (B) indicating no difference in the morphology of the axons either in shape and 
size or myelin thickness. C-D) Representative images of the uninjured gastrocnemius muscle 
from a vehicle (C) or inhibitor (D) treated mouse. The NMJs (red -bungarotoxin) looked similar 
in both treatment conditions as do the axons innervating the NMJs (green NF and SV2). E) 
Quantification of C and D where there was no difference in the percent of innervated NMJs 
between vehicle (blue) and inhibitor (red) treated mice. Vehicle and inhibitor n=3. F) 
Quantification of the amplitudes recorded from the uninjured sciatic nerves in vehicle and 
inhibitor treated mice. There was no difference between treatments which demonstrated that the 
number of axons did not differ with inhibitor treatment. G) Quantification of the latencies from 
uninjured vehicle and inhibitor treated mice. The latencies did not differ between treatment 
conditions indicating that the myelination of uninjured nerves was not altered by inhibitor 












BACE1 inhibition enhances axon regeneration after a sciatic nerve crush injury 
 The first type of acute axonal injury model that we wanted to investigate was a 
sciatic nerve crush. This type of injury completely disconnects the proximal portion of 
the axon from its distal targets while keeping the basal lamina and Schwann cell tube 
intact. This type of injury allows for the proximal stump to extend axonal sprouts through 
the intact Schwann cell tube and be guided towards its appropriate end target.  
We performed sciatic nerve crushes on 9 C57BL/6J WT mice and gave 4 mice 
vehicle food and 5 mice inhibitor food for 2 weeks. We then collected the sciatic nerves 
and gastrocnemius muscles from these mice and determined the extent of regeneration. 
Inhibitor treated mice had many more visible regenerating axons in sciatic nerve cross-
sections than those treated with vehicle (Figure 17 A and B). After quantifying the 
regenerating axons, we found that the vehicle treated mice had 1916.75±456.16 
regenerating axons while the inhibitor treated mice had significantly more regenerating 
axons, at 3378.4±353.78 (Figure 17C; p=0.0366).  
We next determined whether these faster regenerating axons were reaching the 
gastrocnemius muscle leading to improved NMJ reinnervation. When we probed the 
gastrocnemius muscles of the vehicle and inhibitor treated mice, the inhibitor treated 
mice had visibly better NMJ reinnervation (Figure 17D and E). The inhibitor treated 
gastrocnemius muscles were 76.64%±7.726 innervated (n=3) while the vehicle treated 








Fig. 17. BACE1 inhibitors enhance axonal regeneration following a sciatic nerve crush.  
(A-B) Representative EM images of sciatic nerve cross sections from vehicle (A) and inhibitor 
(B) treated mice. Inhibitor treated mice have a greater number of regenerating axons compared to 
the vehicle treated mice. (C) Quantification of the number of regenerated axons in vehicle and 
inhibitor treated mice. Inhibitor treated mice have significantly more regenerated axons. Vehicle 
n=4, inhibitor n=5. (D-E) Representative images of sectioned gastrocnemius muscles stained for 
SV2, NF (both green), and α-BTX (red). The vehicle treated mice (D) have only a few innervated 
NMJs while the inhibitor treated mice (E) have more innervated NMJs. (F) Quantification of the 
number of innervated NMJs between vehicle and inhibitor treated mice indicating enhanced 
innervation after inhibitor treatment. Vehicle n=4, inhibitor n=3. Numbers in parenthesis indicate 
total number of NMJs counted. Bars represent the mean ± standard error. * indicates p < 0.05. 
  
We also determined whether these muscle connections were able to elicit CMAPs 
in the plantar muscles of the foot pad as this is a good way of observing functional 




inhibitor. We then followed the rate of recovery of the CMAP amplitude stimulated at the 
ankle every 2 weeks over 8 weeks (Figure 18). 2 weeks following the injury, neither the 
vehicle nor the inhibitor treated mice had any significant recovery of the CMAP 
amplitude (Figure 18E; vehicle = 0.0602±0.0212 mV; inhibitor = 0.0408±0.0279; 
p=0.324). At 4 weeks, both the vehicle and inhibitor had an improvement in the 
amplitude, however, there was no difference between them (Figure 18E; vehicle = 
2.867±0.273 mV; inhibitor = 2.344±0.125 mV; p=0.414). We suspected that this may be 
related to a deficiency in remyelination. Indeed, we saw a longer latency in inhibitor 
treated mice than vehicle treated at 4 weeks (Figure 18 F; vehicle = 1.688±0.092 ms; 
inhibitor = 2.219±0.143 ms; p = 0.004). When we examined the shape of the CMAP 
traces we noticed that the inhibitor treated mice had many more peaks distributed 
throughout the duration of the CMAP compared to the vehicle treated traces (Figure 18A 
and B). We then calculated the area under the curve and found that the inhibitor treated 
mice had a significantly higher area than the vehicle treated mice (Figure 18G; vehicle = 
3.111±0.193 mV x ms; inhibitor = 4.164±0.393 mV x ms; p = 0.0153). This most likely 
indicated that the inhibitor treated mice has a greater number of axons firing than the 
vehicle treated mice. However, these axons were not able to coherently fire to generate a 
greater CMAP amplitude and reflects a defect in remyelination related to BACE1’s 
processing of neuregulin 1 and the remyelination of the peripheral nerves (56, 57). We 
decided to halt treatment at 4 weeks to allow for remyelination to occur and potentially 
improve in the amplitude of inhibitor treated mice. At 6 weeks, the traces of both the 
vehicle and inhibitor treated mice were firing more synchronously, as seen by the smooth 




different (Figure 18F; vehicle = 1.291±0.0743; inhibitor = 1.085±0.0533; p=0.0568). At 6 
weeks the amplitudes of the inhibitor treated mice were now significantly higher than the 
vehicle treated mice (Figure 18E; vehicle = 6.898±0.496 mV; inhibitor = 8.709±0.714; 
p=0.045). We also observed significantly greater amplitudes in the inhibitor treated mice 
at 8 weeks (Figure 18E; vehicle = 8.335±0.767 mV; inhibitor = 10.732±0.518; p=0.005). 
Taken together, our data shows that BACE1 inhibitor treatment can enhance sciatic nerve 
regeneration and muscle reinnervation, as well as improve CMAP amplitude recovery 
following a complete sciatic nerve crush injury. 
 
Fig. 18. BACE1 inhibition enhances functional repair following a sciatic nerve crush injury.  
A-B) Representative CMAP traces 4 weeks post injury from vehicle (A) and inhibitor (B) treated 
mice. The inhibitor treated trace had many small peaks which is evidence of poor myelination 
impairing the ability of the axons to fire together C-D) Representative traces 6 weeks post injury 
from vehicle (C) and inhibitor (D) treated mice. After being off the inhibitor for 2 weeks, 
remyelination occurred and the axons were able to coordinately fire. E) Quantification of the 
CMAP amplitude recorded every 2 weeks over 8 weeks. Inhibitor treated mice surpassed the 
vehicle treated mice at 6 weeks and continue to separate at 8 weeks. F) Quantification of the 
latency from 4 to 8 weeks following injury. At 4 weeks, the latency of inhibitor treated mice was 
significantly higher than vehicle treated mice. After removing the inhibitor, the latency was no 
longer significantly different, indicating re-myelination had occurred. G) Quantification of the 
area under the curve every 2 weeks for 8 weeks. At 4 weeks, the inhibitor treated group had a 
greater area, reflecting a larger number of axons firing despite not being able to fire together. 






Summary of chapter 3 
 This chapter provided evidence that determined BACE1 inhibitors are able to 
effectively enhance axonal regeneration following a sciatic nerve crush injury. We first 
were able to observe enhanced neurite branching in vitro by treating cultured adult DRG 
neurons with a BACE1 inhibitor. After performing in vivo sciatic nerve crush injuries in 
WT mice, we treated them with a BACE1 inhibitor and monitored the extent of 




significantly increased number of regenerating axons as well as an earlier functional 
recovery time, as evidenced by improved amplitude recordings of the CMAP in the foot 
pad.  
 While being able to enhance regeneration following a nerve crush injury can be 
beneficial to patients, these types of injuries are thought to be less severe, as the 
endoneurium remains intact and the regenerating axon has a higher chance of 
successfully reinnervating its target. Nerve crush injuries also do not model the type of 
axonal reinnervation that would typically occur in cases of peripheral neurodegenerative 
diseases. Due to these limitations of the crush injury model, we next investigated whether 
BACE1 inhibitors are beneficial in enhancing regeneration in a more severe model of 















Chapter 4: Axonal sprouting following a partial nerve injury is 
enhanced by BACE1 inhibition 
Introduction to chapter 4 
  More severe types of peripheral axonal injuries typically involve the disruption of 
the endoneural tube and the Schwann cells lining the axon. This usually occurs following 
a partial or complete nerve transection and is also seen in the peripheral nerves of 
neurodegenerative diseases and neuropathies. Since the proximal and distal portions of 
the nerve become disconnected, it becomes much harder for the proximal stump to 
regrow back into the correct Schwann cell tube and become targeted to the proper end 
organ. In the case of a partial nerve transection, some portion of the nerve is still intact 
and contacting the proper end organ. These intact axons can respond to the local 
denervation and send out collateral axonal sprouts, either nodal, pre-terminal, or terminal, 
to nearby areas of denervation in an attempt to regain partial function. As intact axons 
typically only send out sprouts to close regions of denervation, it stands to reason that 
more extensive degeneration may lead to increased instances of axonal sprouting in 
response to more severe partial nerve injuries. It is also important to be able to trace the 
beginning and end points of potential axonal sprouts as it can be rather difficult to 
determine whether an axon is a true sprout or just passing close by to a NMJ. The current 
model of attempting to sever half of the sciatic nerve is plagued by both of these issues. It 
is quite difficult to accurately sever the exact same percentage of the sciatic nerve and 
ensure that you are severing the nerves that travel to the same muscle you want to use for 




innervated by the sciatic nerve are too thick to satisfactorily image the extremely thin 
axonal sprouts, either due to sectioning limitations or a poor depth of imaging capability 
in whole mounts. Based on this, we wanted to create a more consistent model for 
performing partial nerve transections in a nerve-muscle system that can be adequately 
imaged than what is currently being performed in the sciatic nerve. To do this, we 
utilized the LTN-CMM system, previously characterized by our group (111) and 
expanded on here, to perform more consistent partial nerve injuries in order to study 
whether reduced BACE1 activity also has an effect on terminal axonal sprouting in a 
partial nerve injury model. 
 
Results 
Partial nerve transections can be performed in the lateral-thoracic nerve-cutaneous 
maximus muscle system 
In order to carry out a partial nerve injury to study BACE1 inhibition’s effect on 
axonal sprouting, we severed 2 branches of the LTN and turned the ends away from one 
another to prevent the proximal stump from entering the distal Schwann cell tube. This 
allowed the remaining intact axons to reinnervate the CMM by sending out axonal 
sprouts, as diagrammed in Figure 19A. Under normal circumstances, NMJs in the adult 
mouse are only innervated by a single axon (Figure 19 B). After performing a partial 
nerve transection of the LTN, we were able to identify regions of the CMM where there 
was evidence of degenerating axons closely adjacent to intact axons (Figure 19C). These 
intact axons, theoretically, should have the potential to send out axonal sprouts toward 




axonal injury, NMJs can be multiply innervated as many axonal sprouts can reach the 
denervated NMJs at the same time before undergoing axonal pruning. NMJs with more 
than one axon branch that appear to bridge two NMJs or go off to nowhere could also be 
an innervated NMJ sending out a terminal axonal sprout. Accessing the branches of the 
LTN and being able to consistently sever the same branches was easier than performing a 
consistent partial nerve transection in the sciatic nerve.  
 
Fig. 19. Utilizing the LTN-CMM system to perform partial nerve transections.  
(A) Schematic drawing showing the location of the LTN branches (red) up near the shoulder 
(greyed region). The axons of the LTN run caudally down the length of the mouse after entering 
the CMM up near the shoulder. A partial nerve transection is performed just before the LTN 
enters the CMM by cutting 2 of the visible branches. The intact axons are then able to send out 
axonal sprouts in an attempt to reinnervate nearby denervated NMJs (blue). If the denervated 
NMJ is too far from the intact axon, it remains denervated (black NMJ). (B) A collapsed z-stack 
image from an uninjured whole mounted CMM transgenically expressing YFP in its neurons. 
NMJs were stained red with α-bungarotoxin to determine all the NMJs were innervated in the 
field of view. C) Representative image from a WT mouse 5 days after a partial LTN transection 






The CMM is a thin muscle exclusively comprised of type II muscle fibers 
The following data was published in C. Tallon, K. A. Russell, S. Sakhalkar, N. Andrapallayal, M. 
H. Farah, Length-dependent axo-terminal degeneration at the neuromuscular synapses of type II 
muscle in SOD1 mice. Neuroscience 312, 179-189 (2016). 
In addition to being an ideal model in which a partial motor nerve transection can 
be easily and reliably performed, the LTN-CMM system has other benefits for 
investigating axonal sprouting. In order to investigate axonal sprouting, it is important to 




in fact sprouts and not normal axonal branches. Normally, complete images of muscle 
must be reconstructed from images of sectioned muscle which is often difficult and 
tedious. This problem can be avoided by being able to whole stain and mount the muscle. 
This is most easily done in thin muscles and we set out to confirm the CMM as a thin 
muscle. We collected the CMM from the body by removing the skin off the back of the 
trunk with the CMM remaining attached to the skin. After staining with Hematoxylin and 
Eosin, the CMM was identified as a thin layer of muscle closely associated to the dermis 
of the skin (Fig. 20A, black bar). 
In addition to being quite thin, the LTN-CMM system is also a good system to 
study sprouting from resistant motor fibers. Since fast-fatiguing, α-motor axons 
innervating type II muscle fibers are very resistant to sprouting in response to Botulinum 
toxin A administration (88), we characterized a system to exclusively study a large type 
II muscle and its NMJs. To do this, we first confirmed that the LTN–CMM system in the 
mouse only contained type II muscle. The CMM and soleus muscle were stained for 
myosin heavy chain type I (A4.840) and type II (My32) to identify muscle fiber types. In 
the CMM, only type II fibers were present, as evidenced by the uniform staining in the 
muscle fibers of My32 (Fig. 20B and C). On the other hand, when the soleus muscle was 
simultaneously stained for type I and type II fiber markers, both were present (Fig. 20D). 
Since it is well known that the soleus muscle contains both fibers, this indicated that our 
staining protocol was reliable. Thus, we confirmed that the CMM contains only type II 
muscle fibers and can confidently be used to specifically study the sprouting properties of 





Fig. 20. The CMM is exclusively comprised of type II muscle fibers.  
(A) Musculoskeletal morphology shown through hematoxylin and eosin staining where the CMM 
is indicated by a black bar. (B–D) Myosin heavy chain immunostaining of the CMM where type I 
fibers were labeled with A4.840 (red) and type II fibers were labeled with My32 (green). (B) Low 
magnification fiber type immunostaining shows the CMM is comprised of only type II fibers. (C) 
High magnification of B. (D) Control with soleus tissue showing a mix of type I and type II 
fibers. C. Tallon, K. A. Russell, S. Sakhalkar, N. Andrapallayal, M. H. Farah, Length-dependent 
axo-terminal degeneration at the neuromuscular synapses of type II muscle in SOD1 mice. 











Whole-mounted LTN–CMM can be stained with antibodies 
The following data was published in C. Tallon, K. A. Russell, S. Sakhalkar, N. Andrapallayal, M. 
H. Farah, Length-dependent axo-terminal degeneration at the neuromuscular synapses of type II 
muscle in SOD1 mice. Neuroscience 312, 179-189 (2016). 
One technical problem with using whole muscle tissue is that many antibodies 
cannot penetrate deep into the intact tissue, thus requiring sectioning in order to get 
complete staining. While sectioning allows for easier staining, there is a trade off as it 
becomes more tedious afterward to reconstruct complete NMJs to determine the extent of 
axonal sprouting. We stained the CMM with SV2 and S-100 antibodies to visualize the 
neuronal and glial components of the neuromuscular synapses in whole-mounted tissue. 
We were able to achieve complete staining with the SV2 antibody as indicated by a 
complete overlap of the SV2 and α-bungarotoxin (α-btx) staining in the intact CMM of 
WT mice (Fig. 21A–D). We also observed extensive Schwann cell labeling with the S-
100 antibody (Fig. 21E–H). The ability to carry out effective staining in whole tissue 
provides the LTN–CMM system the unique ability to observe all the components of the 











Fig. 21. Reliable antibody staining of the neuromuscular synapse components in the whole, 
intact CMM.  
(A–D) SV2 antibody staining. (A) SV2 staining of the pre-synaptic component of the 
neuromuscular synapse. (B) α-bungarotoxin staining of the post-synaptic component. (C) YFP 
expressing motor axons. (D) Overlay of (A–C) showing that all three stains overlap completely 
and all the terminals have SV2 staining. (E–H) S-100 antibody staining. (E) S-100 staining of 
Schwann cells. (F) α-bungarotoxin staining of the NMJs. (G) YFP expressing motor axons. (H) 
Overlay of (E–G) showing that the S-100 staining overlaps both the axons and the NMJs. Both 
Schwann cells associated with the axon and those at the terminal can be reliably stained. C. 
Tallon, K. A. Russell, S. Sakhalkar, N. Andrapallayal, M. H. Farah, Length-dependent axo-
terminal degeneration at the neuromuscular synapses of type II muscle in SOD1 mice. 
Neuroscience 312, 179-189 (2016). 
 
Reduced BACE1 activity increases axonal sprouting following a partial nerve injury 
 Following the characterization of a partial nerve transection in the LTN-CMM 
system, we then set out to investigate how reduced BACE1 activity levels impact axonal 




of the LTN intact, in 4 BACE1 KO mice and 4 WT littermates in order to investigate 
whether a complete loss of BACE1 activity had any effect on axonal sprouting. After 7 
days, we collected the CMM to analyze the extent of axonal sprouting. To maximize the 
likelihood of locating axonal sprouts, images were taken from innervated or partially 
innervated regions directly adjacent to regions of denervation since axons will only 
sprout to nearby areas of denervation. For simplicity, only terminal axonal sprouts were 
scored as those are the easiest to define due to the nature of healthy NMJs only having 
one axonal input and any additional axonal outputs, either towards another NMJ or empty 
space, could be scored as a terminal axonal sprout. After examining the images, we 
observed an increase in the number of NMJs that had at least one terminal axonal sprout 
in BACE1 KO mice (Figure 22 A and B, white arrows). We analyzed a total of 868 WT 
and 699 BACE1 KO NMJs and found that there was a significant increase in the 
percentage of NMJs that had terminal axonal sprouts (Figure 22 C; WT = 6.86 ± 1.49%; 
KO = 13.37 ± 1.61%; p = 0.025). This data provided evidence that a genetic loss of 







Fig. 22. Genetically knocking out BACE1 enhances axonal sprouting following a partial 
nerve transection. 
A-B) Representative images of terminal axonal sprouts in WT (A) and KO (B) mice 7 days 
following a partial LTN transection. KO mice have many more NMJs with terminal sprouts as 
indicated by the white arrows. C) Quantification of the percentage of NMJs that have the 
presence of a terminal axonal sprout. KO mice have a significantly higher percentage of NMJs 
with terminal sprouts compared with WT littermates. WT and BACE1 KO n=4. Numbers in 
parenthesis represent the total number of NMJs counted. * indicates p < 0.05. Bars represent 





 We next investigated whether the same principle held true (e.g. enhanced axonal 
sprouting) with the administration of a BACE1 inhibitor. Again, a partial nerve 
transection of the LTN was performed, this time leaving only a single branch intact to 
encourage greater sprouting, in 7 WT mice and gave 3 mice vehicle and 4 mice the 
inhibitor treatment. The mice were treated for 14 days before collecting the CMM and 
looking at the extent of terminal axonal sprouting. We then took images from innervated 
or partially innervated regions directly adjacent to regions of denervation in order to 
maximize the likelihood of imaging an axonal sprout. As with the BACE1 KO 
experiment, only terminal axonal sprouts were quantified to ensure that we were counting 
true axonal sprouts. We observed an increase in the presence of thin axonal sprouts in 
mice treated with the BACE1 inhibitor when compared with the vehicle treated mice 
(Figure 23 A and B, white arrows). After quantifying 262 NMJs from the vehicle treated 
mice and 311 NMJs from the inhibitor treated mice, there was a significant increase in 
the percentage of NMJs that had terminal axonal sprouts in the inhibitor treated mice 
when compared with vehicle treated mice (Figure 23C; Vehicle = 14.315 ± 2.763%; 
Inhibitor = 37.418 ± 2.236%; p = 0.00122). This data, together with the BACE1 KO data 
(from Figure 22), determines that by reducing the activity of BACE1, either genetically 
or pharmacologically, there is a beneficial impact on the extent of axonal sprouting in 






Fig. 23. BACE1 inhibitors enhance terminal axonal sprouting following a partial nerve 
injury. 
A-B) Representative images of a mouse treated with vehicle (A) or inhibitor (B) for 2 weeks 
following a partial LTN transection. White arrows indicate representative terminal axonal 
sprouts. C) Quantification of the percentage of NMJs which have a terminal axonal sprout 
extending out from itself. Inhibitor treated mice have significantly more terminal axonal sprouts 
than mice treated with the vehicle. Vehicle n=3 and inhibitor n=4. Numbers in parenthesis 





Summary of chapter 4 
 The results presented in this chapter provided evidence that partial nerve 
transections can be reliable performed in the LTN-CMM system and can be used to study 
the terminal axonal sprouting response to a partial nerve injury. By severing specific 
branches of the LTN allowing the same branches to remain intact in each mouse studied, 
we were more confident in the reliability of our partial nerve transections. We were also 
able to visualize all the NMJs in the regions imaged and could trace the origin of each 
axon back to its main branch. After performing a partial nerve transection in both BACE1 
KO mice as well as WT mice treated with the MBI-9 BACE1 inhibitor, we observed an 
increase in the percentage of innervated NMJs with the presence one or more terminal 
axonal sprouts. This data indicates that reduced BACE1 activity levels are not only able 
to enhance regeneration from the proximal stump in less severe nerve crush injuries but 
can also lead to increased axonal sprouting in response to more severe partial nerve 
transection injuries. This finding is important not only for patients with various types of 
traumatic peripheral nerve injuries, but may also be a useful mechanism for coaxing 











Chapter 5: Monitoring peripheral nerve degeneration in a 
chronic neurodegenerative disease model 
Introduction for chapter 5 
 Following our finding that BACE1 inhibition can enhance peripheral axon 
sprouting from intact axons following a partial nerve injury, we next wanted to 
investigate whether this principle holds true in a neurodegenerative disease model. We 
settled on the SOD1G93A mouse model of ALS as this model has been very well studied 
with well documented early distal peripheral axonal degeneration occurring before motor 
neuron cell death (131, 132). That the distal axonopathy precedes neuronal cell death 
may provide a window to encourage surviving motor axons to send out axonal sprouts to 
reinnervate areas of denervation and provide some form of prolonged motor function in 
the early stages of the disease. Prior to the application of a BACE1 inhibitor, we first 
characterized the degeneration pattern of the LTN in the SOD1 mouse as the LTN-CMM 
system has never been investigated in the SOD1 mouse. Since the CMM is comprised of 
only type II motor fibers, as confirmed in the previous chapter, we hypothesized that the 
axons of the LTN may degenerate even earlier than those in the sciatic nerve because 
motor fibers innervating type II muscle fibers are more susceptible to degeneration in the 
SOD1 mouse (88, 134, 136, 137). In addition to this, we set out to determine when the 
earliest detectable signs of degeneration appear in the LTN-CMM system as a way to 







The following data was published in C. Tallon, K. A. Russell, S. Sakhalkar, N. Andrapallayal, M. 
H. Farah, Length-dependent axo-terminal degeneration at the neuromuscular synapses of type II 
muscle in SOD1 mice. Neuroscience 312, 179-189 (2016). 
Neither axon nor terminal degeneration was detected at 30 days of age 
To determine the earliest time point that axon degeneration can be detected in the 
LTN–CMM system of SOD1 mice, we analyzed them at 30, 60 and 90 days of age. 
Morphological changes at the NMJs were determined by the extent of denervation of the 
NMJs by scoring the percentage of presynaptic YFP expression overlapping with the 
postsynaptic α-BTX staining (Fig. 24B–D). To determine any physiological changes, we 
measured electrophysiological recordings from 3 different locations on the back (Fig. 
24A). We started with the most caudal recording site and moved rostrally, in order to 
preserve the shorter axons for later recordings at each site. 
At the earliest time point investigated, there was no detectable difference between 
WT mice and the SOD1 mice, both morphologically and physiologically. When we 
scored the percent of innervated NMJs at the caudal, medial, and rostral regions of the 
CMM (Fig. 24E), the WT mice had on average 99.9%, 99.4% and 99% innervation 
respectively (n = 3). The SOD1 mice also had no degeneration with 97.1%, 99.4% and 
99.7% innervation at the caudal, medial, and rostral regions respectively (n = 4). The 
values in the SOD1 mice were comparable to those seen in the WT indicating that 
morphological changes had not occurred by P30 (p > 0.05). We observed a similar result 
with the electrophysiological recordings taken at the three sites (Fig. 24F). In the WT 




medial region, and 2.02 mA at the rostral region (n = 15). The SOD1 mice had similar 
amplitudes (p > 0.05) with the caudal region at 0.34 mA, the medial region at 0.60 mA 
and the rostral region at 1.90 mA (n = 17). The latencies at each region were also similar 
between the WT and SOD1 mice (data not shown). 
 
Fig. 24. No evidence of axonal degeneration in 30-day-old SOD1 mice.  
(A) Schematic diagram of our electrophysiology setup. LTN stimulation is near the shoulder 
(green) while the active (red) and the reference (black) recording electrodes are placed 6 mm on 
either side of the midline (dashed gray line). The three data collection sites are indicated by 
roman numerals with the caudal site measured 6 mm (I), the medial site measured 24 mm (II), 
and the rostral site measured 36 mm (III) anterior to the baseline (blue line). Representative 
CMAP recordings are shown below with their corresponding site denoted by the roman numerals. 
(B–D) Example of fully innervated NMJs in a 30-day-old WT mouse. (B) YFP positively labeled 
motor axons and terminals from YFP transgenic mouse. (C) α-BTX labeled NMJs. (D) Merged 
image of B and C showing all NMJs are innervated by the complete overlap of YFP and α-
bungarotoxin staining. (E) There was no significant difference in the percentage of innervated 
NMJs at each of the collection site for 30-day-old SOD1 (red, n = 4) and WT (blue, n = 3) mice 
(bars represent mean ± standard error). Numbers in parenthesis indicate the total number of NMJs 
counted. (F) CMAP amplitudes at each collection site were not significantly different for 30-day-
old SOD1 (n = 17) and WT (n = 15) mice (points represent mean ± standard error). C. Tallon, K. 
A. Russell, S. Sakhalkar, N. Andrapallayal, M. H. Farah, Length-dependent axo-terminal 












Marked degeneration appears at the caudal region by 60 and 90 days 
When we examined 60-day-old mice, we observed evidence of degeneration in 
the SOD1 mice compared with the WT mice. The largest difference in NMJ innervation 
was seen at the caudal site, with an average of only 44.5% of the NMJs being innervated 
in the SOD1 mice compared with 97.9% innervation in the WT mice (Fig. 25A–C; SOD1 
n = 3; WT n = 4; p = 0.0093). There was also a slight decrease in the number of 
innervated NMJs at the medial region of the back with 77.8% innervation in the SOD1 
mice compared with 98.7% in the WT mice (p > 0.05). At the rostral site, there was no 
significant difference between the WT and the SOD1 mice (97.1% and 95.8% 
respectively; p > 0.05). Examining the neurophysiological changes in the SOD1 mice at 
60 days revealed a decrease in the amplitudes of the CMAP at both the caudal (Fig. 25D; 
WT amplitude = 0.36 mA, SOD1 amplitude = 0.16 mA; WT n = 21, SOD1 n = 17; p = 
0.00031) and medial sites (Fig. 25D; WT amplitude = 0.79 mA, SOD1 amplitude = 0.50 
mA; p = 0.029). There was no significant difference in the amplitudes at the rostral site, 
in agreement with the lack of denervation seen at the rostral region (Fig. 25D; WT 












Fig. 25. Axonal degeneration is evident by 60 days in SOD1 mice at the caudal site but not 
the rostral site.  
(A, B) A morphological comparison of the caudal site from 60-day-old WT mice (A) and 60-day-
old SOD1 mice (B) showing far more denervated NMJs in the SOD1 mice than the WT. YFP 
expressing axons are shown in green and α-bungarotoxin labeled NMJs are in red. (C) A 
quantification of the percentage of innervated NMJs between 60-day-old WT mice (blue, n = 4) 
and SOD1 mice (red, n = 3). The caudal region has the greatest decline in innervation while the 
rostral region remains relatively intact. Bars represent mean ± standard error. Numbers in 
parenthesis indicate the total number of NMJs counted. (D) CMAP amplitudes at the caudal and 
medial regions in SOD1 mice (n = 17) showed a significant decline in amplitude when compared 
to WT mice (n = 21). Points represent mean ± standard error. ∗ indicates p < 0.05. C. Tallon, K. 
A. Russell, S. Sakhalkar, N. Andrapallayal, M. H. Farah, Length-dependent axo-terminal 





At 90 days of age, we observed further degeneration of the LTN axons. The 
caudal site of the SOD1 mice showed an even greater decrease in innervation with only 
24.3% innervated compared to 88.4% in the WT (Fig. 26A, B, E; SOD1 n = 4, WT n = 3; 
p = 0.00091). The medial region of the SOD1 mice was only 55.3% innervated while the 
WT mice had 90.7% innervation (Fig. 26E; p = 0.0050). It was only at 90 days that 
degeneration in the SOD1 mice was apparent at the rostral site (Fig. 26C, D, E). Only 
59.8% of the NMJs were innervated in the SOD1 mice while the WT mice had 93.9% 
innervation (Fig. 26E; p = 0.029). When we compared the CMAP amplitudes of WT and 
SOD1 mice, there was a further decrease in the amplitudes at the caudal site with the 
SOD1 mice at 0.13 mA compared to the WT amplitude of 0.27 mA (Fig. 26F; WT n = 
19, SOD1 n = 19; p = 0.013). The medial site also continued to decline, with the SOD1 
amplitude at 0.37 mA while the WT remained normal at 0.75 mA (Fig. 26F; p = 0.020). 
The amplitude at the rostral site in the SOD1 mice was 1.66 mA which was slightly 













Fig. 26. Axonal degeneration is apparent at the rostral site at 90 days of age in SOD1 mice.  
(A, B) Representative images at the caudal site of WT mice (A) and SOD1 mice (B) show 
increased degeneration with extensive denervation in the SOD1 mice while the WT remain fully 
innervated. YFP expressing axons are shown in green and α-bungarotoxin labeled NMJs are in 
red. (C, D) Representative images at the rostral site of WT mice (C) and SOD1 mice (D) show 
degeneration at the rostral site in SOD1 mice while the WT is intact. (E) Quantification of the 
percentage of innervated NMJs in 90-day-old mice showing increased denervation at the caudal 
region and medial sites and significant degeneration appearing at the rostral region in SOD1 mice 
(red, n = 4) compared with WT mice (blue, n = 4). Bars represent mean ± standard error. 
Numbers in parenthesis indicate the total number of NMJs counted. (F) CMAP amplitudes are 
significantly reduced at the caudal and medial regions in SOD1 mice (n = 19) at 90 days when 
compared with WT mice (n = 19). The rostral region also shows a slight decrease in SOD1 mice 
but it did not reach significance. Points represent mean ± standard error. ∗ indicates p < 0.05. C. 
Tallon, K. A. Russell, S. Sakhalkar, N. Andrapallayal, M. H. Farah, Length-dependent axo-
terminal degeneration at the neuromuscular synapses of type II muscle in SOD1 mice. 









Physiological changes at the distal LTN occurs earlier than the sciatic nerve 
We next compared the time course of the physiological changes in the LTN–
CMM system with the time course in the sciatic nerve of SOD1 mice. Similarly to the 
LTN–CMM, the sciatic nerve did not show any difference in the CMAP amplitude 
between the WT (n = 6) and SOD1 (n = 6) mice at 30 days of age at both the proximal 
and distal stimulation sites (Fig. 27B; p > 0.05). When we examined P60 mice, there was 
again no significant difference in amplitude between the WT (n = 7) and SOD1 (n = 8) 
mice at both sites (Fig. 27C; p > 0.05). This differs from what was observed in the LTN–
CMM system as there was a significant decrease in the CMAP amplitude at the caudal 
site by 60 days, whereas in the sciatic nerve there was no decrease in the amplitudes at 
either stimulating site. Only at 90 days were we able to detect a significant decrease in 
the CMAP amplitudes in the sciatic nerve for both the distal (p = 0.050) and proximal 
stimulation sites (p = 0.003) (Fig. 27D; WT n = 18, SOD1 n = 19). The ability to detect 
degeneration earlier in the LTN–CMM system makes it a more robust and attractive 













Fig. 27. The sciatic nerve shows a decrease in CMAP amplitude at 90 days.  
(A) Schematic diagram showing electrode placements for the left sciatic nerve recordings. The 
recording electrodes were placed in the foot pad as indicated by the black electrode. The sciatic 
nerve was stimulated separately at each of the green electrodes with the proximal or distal 
stimulation sites labeled. The proximal site was located 31 mm from the recording electrodes and 
the distal site was 12 mm from the recording electrodes. (B) At 30 days old, SOD1 mice (red, n = 
6) show no significant difference in recordings for both the distal and proximal stimulating sites 
when compared with WT mice (blue, n = 6). (C) Again, at 60 days of age, SOD1 mice (red, n = 
8) do not show any significant difference from the WT mice (blue, n = 7). (D) Only at 90 days of 
age do SOD1 mice show a significant decline in the CMAP amplitudes when stimulated at either 
the distal or proximal sites. The inset shows representative traces at the proximal site in WT mice 
(blue, n = 18) and SOD1 mice (red, n = 19) at 90 days old. Bars represent mean ± standard error. 
∗ indicates p < 0.05. C. Tallon, K. A. Russell, S. Sakhalkar, N. Andrapallayal, M. H. Farah, 
Length-dependent axo-terminal degeneration at the neuromuscular synapses of type II muscle in 




Limited sprouting of the surviving LTN axons 
Next, we searched for evidence of axonal sprouting from the surviving axons in 
the SOD1 mice. To do this, we used the same preparations as those used to characterize 
the extent of NMJ denervation and looked for the presence of extremely thin terminal 
sprouts. Terminal sprouting was not robust in the 30-day-old mice, as was expected given 
the lack of degeneration seen in Fig. 24. We detected some sprouting at the caudal and 
medial sites in both the 60- and 90-day-old SOD1 mice (Fig. 28). Figs. 28A–C show an 
image of two terminal sprouts in a 60-day-old SOD1 mouse as indicated by the white 
arrows in Fig. 28C. While there was evidence of sprouting, there was a very limited 
sprouting at 60 days (Fig. 28D, red bars, n = 5). At the caudal region only 0.35% of 
NMJs had a terminal sprout and the medial region had 0.42%. There were no sprouts 
detected at the rostral region as there was no denervation observed to initiate the 
sprouting machinery. At 90 days, when the degeneration was more extensive, there was 
an increase in the percentage of NMJs with terminal sprouts (Fig. 28D, blue bars, n = 6). 
The caudal, medial, and rostral regions had 1.47%, 1.0%, and 0.54% of NMJs with 
terminal sprouts respectively. Despite this increase, the extent of sprouting is still very 
limited and cannot keep up with the degenerative process. The presence of these sprouts, 
however limited, does indicate that type II fibers do have the capacity for some limited 
regeneration in the SOD1 mouse model. With the advantage of being able to whole 
mount the intact CMM, we were able to image the origin of the sprouts and easily 
determine whether it was a terminal sprout or not. The LTN–CMM system provides a 
unique model to selectively investigate potential strategies for axonal protection and 





Fig. 28. SOD1 mice show very limited axonal sprouting.  
(A–C) Representative images of sprouting in a 60-day-old SOD1 mouse (A) YFP labeled motor 
axons and presynaptic terminals. (B) α-bungarotoxin labeled NMJs. (C) Combined images of (A) 
and (B) showing that the medial region in an SOD1 mouse has the capacity for axonal sprouting 
with terminal sprouts indicated by white arrows. (D) Quantification of the percentage of NMJs 
with terminal sprouts at the three regions (caudal, medial, and rostral). 60-day-old mice are 
shown in red (n = 5). Ninety-day-old mice are shown in blue (n = 6). Numbers in parenthesis 
indicate the number of NMJs counted. Bars represent mean ± standard error. C. Tallon, K. A. 
Russell, S. Sakhalkar, N. Andrapallayal, M. H. Farah, Length-dependent axo-terminal 






Summary of chapter 5 
 In this chapter, we identified a length dependent degeneration pattern of the LTN 
in the SOD1G93A mouse model of ALS. The longest axons reaching the caudal region of 
the CMM were the first to show evidence of denervation by 2 months of age. As the mice 
aged, the degeneration moved further up the CMM towards the shorter axons in the 
rostral region. We determined that the earliest time point of detectable denervation 
occurred around 2 months of age, which was 1 month earlier than the window of 
detectable denervation in the sciatic nerve system. We were also able to identify evidence 
of a very limited amount of terminal axonal sprouts from the surviving axons at 2 and 3 
months of age. Based on this data, we determined that the optimal treatment window for 
BACE1 inhibitors would be to begin treatment when the mice are 1 month old, before 
significant degeneration is detected, in order to maximize the effects the inhibitors may 










Chapter 6: BACE1 inhibitors as potential therapeutics to 
enhance peripheral nerve regeneration in the ALS mouse 
model 
Introduction 
 Following our characterization of the LTN-CMM system in the SOD1G93A mouse 
model of ALS, we were able to determine that the optimal time to begin the BACE1 
inhibitor treatment was when the mice were 1 month of age. This time point allowed us 
to start treatment before any significant denervation was detected in the CMM and would 
therefore provide the greatest chance of exerting any effect on the extent of innervation. 
In order to monitor whether the BACE1 inhibitors were having any effect on NMJ 
innervation, we used the same end point analyses used to determine the degeneration 
profile, namely the percent of innervated NMJs and the amplitude of the CMAP along the 
CMM. In addition to determining whether there was any effect on the level of innervation 
in these mice, we also explored whether BACE1 inhibitors would be able to enhance the 
limited terminal sprouting identified in the previous chapter. Based on our findings in the 
partial nerve transection study with the BACE1 inhibitor administration, we hypothesize 
that we will also find an increased level of sprouting in the BACE1 inhibitor treated 
SOD1 mice. We also set out to investigate a possible mechanism for how BACE1 
inhibition may be influencing expression levels of the cell adhesion molecule CHL1, a 







BACE1 inhibitors improve muscle innervation and electrophysiological values in an 
ALS mouse model after 1 month of treatment 
 After determining the progression of axonal degeneration in the early stages of 
disease in the SOD1G93A mouse model of ALS (112), we were able to use this data as a 
way of determining a dosage schedule for the BACE1 inhibitors. At 1 month of age, the 
mice did not have much degeneration, as evident by the complete innervation of the 
CMM. By 2 months, we saw degeneration beginning to occur in the longest LTN axons 
innervating the region closest to the tail. Based on this observation, we began treating the 
mice with either the vehicle or inhibitor at 1 month of age, before degeneration becomes 
apparent. We then allowed the mice to continue eating the vehicle or inhibitor food for 
another month before performing electrophysiological recordings at the caudal region of 
the CMM and then collecting the CMM for morphological analysis.  
We performed these experiments with the more clinically relevant MBI-9 BACE1 
inhibitor. After imaging the CMM from vehicle and inhibitor treated mice, it was 
apparent that there was a difference in the extent of innervation between the two 
conditions. At the caudal region, where the longest axons were reaching, the vehicle 
treated mice appeared to have fewer innervated NMJs than the inhibitor treated mice 
(Figure 29 A and B). Following quantification of the percentage of completely innervated 
NMJs in the vehicle and inhibitor treated mice, we observed a significantly greater 
percentage of innervated NMJs in the inhibitor treated mice compared to those with 
vehicle (Figure 29C; Vehicle = 56.40±0.378%, n=3; Inhibitor = 87.27±0.797%, n=3; p = 




however (Figure 29C; WT = 100%, n=3; p = 8.96E-5). At the medial region, we did not 
observe any significant difference between the vehicle and inhibitor treated mice, most 
likely due to there being only minimal degeneration present (Figure 29C; Vehicle = 
92.519±3.231%; Inhibitor = 96.187±2.515%; p = 0.421). When we recorded the caudal 
CMAP amplitudes in vehicle and inhibitor treated mice we saw significantly greater 
amplitudes in the inhibitor treated mice than the vehicle treated mice (Figure 29 D and E; 
p = 0.0103). The vehicle treated mice had an amplitude of 0.916 ± 0.0636mV (n=23) 
while the inhibitor treated mice had an amplitude of 1.238 ± 0.091mV (n=23). Despite 
there being a deficit in the percentage of innervation between the inhibitor treated SOD1 
mice and the WT mice, the innervation that was present in the inhibitor treated mice was 
sufficient to bring their amplitudes to a similar value as those of the WT mice (WT = 















Fig. 29. 1 month MBI-9 BACE1 inhibitor treatment improves morphological and 
physiological repair in SOD1 mice.  
(A-B) Representative images of the CMM from the caudal section of a mouse treated for 1 month 
with vehicle (A) and the Merck inhibitor (B). Axons labeled green and NMJs labelled with red α-
BTX. (C) Quantification after 1 month of treatment of the percentage of NMJs that are fully 
innervated in uninjured WT (black, n=3), vehicle treated SOD1 (blue striped, n=3), and inhibitor 
treated SOD1 mice (red dotted, n=3). At the caudal region, while the SOD1 treated with inhibitor 
had significantly fewer innervated NMJs compared to uninjured WT mice, there was a large, 
significant improvement in innervation from vehicle treated SOD1 mice. At the medial region, 
the disease had not progressed far enough for a significant reduction in innervation with either 
vehicle treatment or inhibitor treatment. Numbers in parenthesis represent total number of NMJs 
counted. WT n=; vehicle n=; inhibitor n= (D) Representative traces of CMAP recordings at the 
caudal site from vehicle treated SOD1 mice (blue) and inhibitor treated SOD1 mice (red). (E) 
Quantification of the average CMAPs recorded from WT mice (black), vehicle treated SOD1 
mice (blue striped), and inhibitor treated SOD1 mice (red dotted). Inhibitor treatment 
significantly enhanced CMAP recordings when compared with vehicle treated SOD1 mice. There 
was no significant difference in CMAP recordings between inhibitor treated SOD1 mice and WT 
mice. WT n=25, vehicle n=23, and inhibitor n=23. Bars represent mean ± standard error. * 






In addition to the MBI-9 BACE1 inhibitor, we also wanted to carry out these 
experiments with a second BACE1 inhibitor to rule out the differences being due to the 
drug specifically and not general BACE1 inhibition. We followed the same dosing 
schedule with the LY2886721 BACE1 inhibitor and once again monitored the extent of 
innervation of the CMM as well as the CMAP amplitudes in mice treated with the 
LY2886721 inhibitor and compared it to the vehicle treated mice. Like the MBI-9 
inhibitor, there was a significant increase in the percentage of innervated NMJs in the 
inhibitor treated mice compared to the vehicle treated mice (Figure 30A; vehicle = 




improvement in the CMAP amplitudes of the inhibitor treated mice compared with the 
vehicle treated mice (Figure 30B; Vehicle = 0.339±0.0538 mV, n=12; Inhibitor = 
0.530±0.0619 mV, n=14; p = 0.017). Together with the MBI-9 data, we determined that 
pharmacologically inhibiting BACE1 for 1 month led to increased NMJ innervation in 
the SOD1G93A ALS mouse model. This improved NMJ innervation is also reflected in the 
CMAP amplitudes recorded from inhibitor treated mice. 
 
 
Fig. 30. 1 Month of LY2886721 BACE1 inhibitor treatment enhances morphological and 
electrophysiological values in SOD1 mice. 
A) Quantification of the percentage of innervated NMJ from WT (black, n=3), vehicle treated 
SOD1 mice (blue, n=3), or LY2886721 treated SOD1 mice (orange, n=3). LY2886721 treatment 
greatly increased NMJ innervation compared to vehicle. B) Quantification of the CMAP 
amplitudes recorded from vehicle and inhibitor treated mice. LY2886721 treatment improved the 
amplitudes of the CMAPs recorded at the caudal site compared with the vehicle treated mice. 






BACE1 inhibitor treatment only improves morphological repair after 2 months of 
treatment 
 After determining that BACE1 inhibition is able to improve both morphological 
and physiological function following 1 month of treatment, we next extended the 
treatment window and determined whether there was any improvement following 2 
months of treatment. Like the 1 month treatment, we began treating the mice with the 
MBI-9 BACE1 inhibitor at 30 days of age and allowed them to continue on the treatment 
for 2 months before performing electrophysiological recordings and collecting the CMM 
for morphological analysis. Qualitative observations indicated that the BACE1 inhibitor 
treated mice had an increased number of innervated NMJs when compared with the 
vehicle treated mice (Figure 31 A and B). Following quantification (Figure 31C), the 
inhibitor treated mice had significantly higher innervation than the vehicle treated mice at 
the caudal (vehicle 35.57±6.614%, n=6; Inhibitor = 53.45±4.823%, n=7; p = 0.0477), 
medial (vehicle 43.89±5.23%, n=6; Inhibitor = 69.25±6.136%, n=7; p = 0.0104), and 
rostral region (vehicle 62.28±6.714%, n=6; Inhibitor = 83.41±2.826%, n=7; p = 0.0107). 
Despite the increased innervation with the inhibitor treatment, the disease progression 
appears to have continued with lower innervation percentages compared to the inhibitor 
treated values after 1 month of treatment. The further progression of the disease is also 
reflected in the electrophysiological analysis of the CMAP amplitude after 2 months of 
treatment (Figure 31 D – F). While the caudal region following 1 month of treatment 
showed a significant increase in the amplitude, after 2 months of treatment we were only 
able to observe a very weak trend at both the caudal (Figure 31D; Vehicle 0.398±0.0345 




Vehicle 1.838±0.199 mV, n=34; Inhibitor = 2.12±0.216 mV, n=36; p = 0.335) region of 
the CMM. At the rostral region, there was virtually no difference between the inhibitor 
and vehicle treated mice (Figure 31F; Vehicle 6.713±0.548 mV, n=34; Inhibitor = 
6.589±0.509 mV, n=36; p = 0.925). We hypothesize that this loss of significance 
following 2 months of treatment may be due to the disease process overwhelming the 
repair process.  
 
Fig. 31. 2 month Merck BACE1 inhibitor treatment improves morphological repair but not 
functional repair.  
(A-B) Representative images of the CMM from the caudal section of a mouse treated for 2 
months with vehicle (A) and the Merck inhibitor (B). Axons labelled green and NMJs labelled 
with red α-BTX. (C) Quantification after 2 months of treatment of the percentage of NMJs that 
are fully innervated in uninjured WT (black, n=3), vehicle treated SOD1 (blue striped, n=6), and 
inhibitor treated SOD1 mice (red dotted, n=7). At this stage, the disease has progressed far 
enough to be able to detect a significant drop in innervation at all three locations along the CMM 
in vehicle treated SOD1 mice. Inhibitor treated mice had significantly more innervated NMJs 
compared with the vehicle treated mice. Numbers in parenthesis represent total number of NMJs 
counted. (D-F) Quantification of the CMAP recordings in vehicle treated SOD1 (blue striped, 
n=34), and inhibitor treated SOD1 mice (red dotted, n=36) at the caudal (D), medial (E), and 
rostral sites (F). There was no significant difference between the vehicle and inhibitor treated 
mice at all three regions however, there is a very weak trend with the inhibitor having a small 
improvement in amplitude at both the caudal (D) and medial regions (E). Bars represent mean ± 











Axonal sprouting is enhanced by reducing BACE1 activity 
 To further understand whether this increased innervation following BACE1 
inhibition in the SOD1 mouse was due to a neuroprotective effect or increased 
reinnervation, we investigated the extent of terminal axonal sprouting. As determined 
earlier, the extent of axonal sprouting in SOD1 mouse at 60 days of age was extremely 
minimal (112). We observed very few sprouts in both vehicle and inhibitor treated mice 
however it appeared to be slightly easier to capture an image of sprouts in the inhibitor 
treated mice compared (Figure 32 A-B). More mice need to be studied in order to 
definitively conclude that one month of inhibitor treatment enhances axonal sprouting.  
 By the time the mice are 3 months of age, the extent of axonal sprouting has 
increased and it is easier to capture images of axonal sprouts. Figures 32C and D 
showcase representative images from vehicle treated and inhibitor treated caudal regions, 
respectively. There were many more visible terminal axonal sprouts in the inhibitor 
treated mice compared to vehicle treated mice, as indicated by the white arrows. 
Following quantification, there was a significant increase in the percentage of NMJs with 
the presence of one or more terminal axonal sprouts (Figure 32E; Vehicle 3.52±0.989%, 
n=6; Inhibitor = 9.29±1.976%, n=6; p = 0.026). Based on this finding that terminal 
axonal sprouting was increased following BACE1 inhibitor treatment in the SOD1 
mouse, we believe that the increased innervation is due to enhanced axonal reinnervation 





Fig. 32. BACE1 inhibition enhances axonal sprouting in disease.  
(A-B) Representative sprouting images of SOD1 mice treated for 1 month with vehicle (A) or the 
inhibitor (B). Axons are labeled green and NMJs are labeled red. White arrows point to terminal 
axonal sprouts. Inset shows magnified terminal axonal sprout. (C-D) Representative sprouting 
images of SOD1 mice treated for 2 months with vehicle (C) or the inhibitor (D). Inset shows 
magnified terminal-to-terminal axonal sprout. (E) Quantification of the percentage of NMJs with 
terminal sprouts after 2 months of treatment. Mice treated with BACE1 inhibitors (n=6) have an 
increased percentage of NMJs with terminal axonal sprouts compared to vehicle treated mice 
(n=6). Numbers in parenthesis represent total number of NMJs counted. Bars represent mean ± 





L1/CHL1 expression levels are increased in SOD1G93A mice following BACE1 
inhibition  
 After determining that BACE1 inhibitors increase NMJ innervation in the early 
stages of disease in the SOD1 mouse, most likely via enhanced axonal sprouting, we next 
explored a potential molecular mechanism for how this phenomenon was occurring. 
Since BACE1 is a fairly promiscuous enzyme, we decided to narrow our initial 
investigation to a logical, well-known candidate. In order for axons to sprout and be 
guided towards a target they need to interact with the supporting Schwann cell tubes. We 
therefore hypothesized that BACE1 may be modulating expression levels of neuronal 
adhesion molecules as a way of controlling this axon-Schwann cell interaction. 
Previously, CHL1, a neuronal cell-cell adhesion molecule, had been identified and 
verified as a known substrate of BACE1 (49). We decided to investigate whether the 
levels of full-length CHL1 was altered in SOD1 mice treated with a BACE1 inhibitor. 
After collecting the spinal cord and processing the tissue for Western blot analysis, we 
observed a significant increase in the normalized intensity of the inhibitor treated bands 
compared with the vehicle treated bands (Figure 33A and B; Vehicle = 0.868±0.0419, 
n=4; inhibitor = 1.032±0.216, n=4; p=0.0149). We believe that this data lends some 
support to our hypothesis that BACE1 activity levels modulate expression levels of full-
length adhesion molecules as a way of regulating axonal outgrowth. While fairly 








Fig. 33. BACE1 inhibition alters L1/CHL1 expression levels in SOD1 mice. 
(A) Representative Western blot of spinal cord tissue collected from SOD1G93A mice following 1 
month of either vehicle or BACE1 inhibitor treatment. GAPDH was used as a loading control for 
normalization calculations. (B) Quantification of the Western blots following normalization of the 
CHL1 band intensity to the GAPDH band intensity. BACE1 inhibitor treatment led to a 
significant increase in the intensity of the CHL1 bands. Bars represent mean ± standard error. * 
indicates p < 0.05. 
 
Summary of chapter 6 
 Based on the data presented in this chapter, we determined that pharmacological 
inhibition of BACE1 was able to improve NMJ innervation and CMAP amplitudes in the 
SOD1 mice after 1 month of treatment. When we extended the treatment time to 2 
months, we still observed improved NMJ innervation, however, a significant 
improvement of the CMAP amplitude was lost. This lack of functional improvement may 
be attributed to the progression of the disease already beginning to overwhelm the repair 




available for sprouting. Indeed, we did see an increased percentage of NMJs which had 
terminal sprouts after 2 months of treatment, indicating that the greater percentage of 
innervated NMJ may be in part due to increased axonal sprouting from intact axons. We 
were also able to detect a significant increase in the expression level of full length CHL1, 
providing early evidence that CHL1 processing by BACE1 may be a mechanism by 
which axons are able to regulate the extent of axonal regeneration and sprouting that 



















Chapter 7: Conclusions 
 Overall, this dissertation set out to explore 3 major questions pertaining to how 
BACE1 activity levels are related to peripheral nerve regeneration. The first was whether 
neuronal BACE1 overexpression led to impaired axonal regeneration, in contrast to 
improved regeneration observed in BACE1 KO mice. The second was to determine if 
BACE1 inhibitors can enhance peripheral nerve regeneration and axonal sprouting 
following acute nerve injuries. Finally, the third question was to identify if BACE1 
inhibitors could improve early regeneration in the SOD1G93A mouse model of ALS. In the 
first portion of the data presented here, we were able to show that transgenic mice that 
overexpress human BACE1 in their neurons do have impaired axonal regeneration 
following a sciatic nerve crush, without any differences in macrophage recruitment and 
axonal debris clearance. Together with the BACE1 KO studies conducted earlier, we can 
conclude that BACE1 activity levels do inversely influence peripheral nerve 
regeneration. We were then able to take this relationship and apply it as a way of 
therapeutically enhancing peripheral nerve regeneration and sprouting in both a nerve 
crush and a partial nerve transection injury model by administering BACE1 inhibitors 
following injury. In addition to enhancing peripheral nerve repair following acute 
injuries, we also demonstrated that BACE1 inhibitor treatment can improve NMJ 
innervation in the early stages of disease in an ALS mouse model. These major findings 
have many implications beyond their therapeutic potential and also provide insight into 
how we can model peripheral nerve injuries, ways that the repair machinery is able to 
regulate peripheral nerve regeneration, and possible insights into ways that disease and 




findings, as well as other potential conclusions that may be considered as a result of these 
findings, are discussed in greater detail below. 
 
Increased BACE1 activity levels are detrimental to peripheral nerve 
repair 
We had previously shown that knocking out BACE1 enhances regeneration 
following a sciatic nerve crush (25). Taken together with the results outlined in chapter 2, 
it would seem that BACE1 activity levels are involved in regulating the activation or 
inhibition of the repair process in neurons after injury. Based on what we have observed, 
there is an inverse relationship between the levels of BACE1 expression and the 
effectiveness of peripheral nerve regeneration. When BACE1 activity levels are high, 
peripheral nerves have a reduced regeneration response. Since a crucial component to 
whether or not the peripheral nervous system is effective at repairing itself after injury is 
the time it takes the axons to reach their target (9), having an excessive amount of 
BACE1 present could be detrimental to the recovery process. In fact, it may be 
interesting to explore endogenous BACE1 activity levels in animals that have different 
rates of axonal growth and explore whether there is any correlation between the level of 
BACE1 expression following injury and the rate of axonal growth. That this data 
identifies high levels of BACE1 activity as being detrimental to peripheral nerve 
regeneration, it suggests that administering a BACE1 inhibitor to patients after suffering 
a peripheral nerve injury could help improve their functional recovery. Fortunately, 
BACE1 inhibitors are currently being heavily investigated for safety and efficacy by 




attractive route to explore in terms of therapeutically improving peripheral nerve 
regeneration (42, 164, 176). We were able to exploit this interest in developing BACE1 
inhibitors and obtained multiple drugs to use in my studies regarding potential 
therapeutics for treating peripheral nerve injuries. 
 
Potential BACE1 mechanisms 
In addition to understanding how BACE1 activity levels influence peripheral 
nerve regeneration following a peripheral nerve injury, the use of mice that selectively 
overexpressed BACE1 in their neurons provided interesting insight into whether the 
changes in regeneration due to BACE1 expression levels could be isolated to the neuron 
alone or whether the changes required altered expression levels in the supporting cells as 
well. The results presented in chapter 2 indicated that BACE1 overexpression within the 
neuron is sufficient to impair regeneration without altered levels in macrophages or 
Schwann cells. However, a peripheral axon injured by trauma or disease is always in 
close contact with a Schwann cell membrane and that interaction is required for regrowth. 
Two substrates of BACE1, L1 and CHL1 (49, 159), might be the neuronal molecules that 
BACE1 acts through in regulating peripheral axon regeneration. CHL1 promotes neurite 
outgrowth in culture and possibly does so in vivo through Schwann cell–regenerating 
axon interaction (98, 177). L1 also promotes the outgrowth of cultured dorsal root 
ganglion neurites on co-cultured Schwann cells (178, 179). By potentially increasing 
their cleavage, the BACE1 Tg axons may have less interaction with Schwann cell tubes. 
Conversely, it may be hypothesized that reducing BACE1 expression may lead to 




enhance the interactions between Schwann cells and axons, leading to enhanced 
outgrowth. Further studies need to be conducted in order to rule out whether the 
regeneration deficits in BACE1 Tg mice are solely due to a neuronal component or 
whether it is based on the interactions between the Schwann cell and axon involved in the 
regenerative process. It would also be beneficial to carry out nerve injury experiments in 
conditional KO mice that specifically lack BACE1 in neurons, Schwann cells, or 
macrophages separately to further tease out the individual roles of each cell type. 
 
BACE1 activity levels may be further complicating repair in disease and 
ageing 
The finding of reduced regeneration in BACE1 Tg mice also has interesting 
implications for other neurodegenerative diseases, especially AD. It is now well known 
that BACE1 activity is required for the generation of Aβ peptides present in the plaques 
found in AD (15, 39, 41, 180). In AD brains, elevated levels of BACE1 have been 
identified in addition to the amyloid beta plaques (181-183). In mice overexpressing 
human BACE1, neurodegeneration was apparent by 6 months of age, with or without the 
presence of plaques, suggesting that the formation of plaques may not be necessary for 
neurodegeneration (44). The increased neurodegeneration seen in these mice coupled 
with our finding that BACE1 overexpression leads to impaired regeneration supports 
BACE1 inhibitors as a potential therapy for AD. The benefits would be two-fold: Firstly, 
inhibiting BACE1 would reduce the neurodegeneration occurring. Secondly, lowering 




These findings may also shed some light on to the mechanisms underlying poorer 
regenerative repair seen with aging peripheral nerves (14, 184-188). While studies on 
BACE1 activity levels in the aging peripheral nervous system have not been performed, 
an increase in BACE1 activity has been seen in aging mouse, monkey and human brains 
(189). This increase in activity has been hypothesized as a potential reason why AD is a 
disease of aging, since increased BACE1 activity leads to increased Aβ production (189). 
The findings in outlined in chapter 2 indicate that an increase in BACE1 expression and 
activity leads to impaired axonal repair. If the increased BACE1 activity associated with 
aging, as seen in the central nervous system (181-183), holds true in the peripheral 
nervous system, this may be a potential mechanism underlying reduced axonal repair in 
elderly patients. This has clinical significance as it may also be beneficial to provide 
elderly patients with a BACE1 inhibitor after undergoing nerve damage to help improve 
repair and recovery. 
 
The LTN-CMM system is useful for studying peripheral nerve repair 
following acute nerve trauma and in neurodegenerative diseases 
 In order to accurately study whether BACE1 inhibitors would have an impact on 
peripheral nerve regeneration, we wanted to develop a system that would provide an easy 
way to consistently perform a partial nerve transection and easily trace the origin and end 
point of axonal sprouts. In chapter 4, we were able to show that the LTN-CMM system is 
a good model for performing partial nerve transection injuries and monitoring the 
sprouting response following BACE1 inhibitor treatment. The LTN innervates only a 




accessed before it enters the CMM. This branching pattern made the CMM advantageous 
over the sciatic nerve because it allowed greater control over the percentage of axons that 
were left intact and is a much simpler surgery to perform than trying to access the ventral 
roots to perform a more constant sciatic nerve injury. We were also able to trace axonal 
sprouts in detail throughout the CMM which allowed for accurate quantification of the 
extent of axonal sprouting. Due to the anatomy of how the CMM is innervated by the 
LTN and the sensory nerve, it is possible to remove a large portion of the sensory nerves, 
making it easier to image the motor axons and its axonal sprouts. The CMM is also a very 
thin muscle and is easy to whole mount and stain, providing the ability to visualize all the 
axons innervating all the NMJs as well as the extremely thin axonal sprouts. Imaging 
axonal sprouts is very challenging in thicker muscle whole mounts and an even greater 
challenge in muscle sections as they must be reconstructed in order to accurately quantify 
an axonal projection as a terminal sprout. 
In chapter 5 we were able to show that the LTN-CMM system is also a good 
candidate for monitoring changes in the SOD1G93A ALS mouse model. By using the 
LTN–CMM system, it allowed us to observe that the longer axons in the caudal region 
showed more extensive degeneration at 60 days of age, while the shorter rostral region 
only had moderate degeneration at 90 days. This degeneration was detected by both the 
extent of NMJ denervation as well as a functional decline using electrophysiological 
recordings of the CMAP. Fischer et al. (132) showed that the degeneration in the SOD1 
mouse model begins in the periphery, long before it is observed at the level of the spinal 
cord. While this study was instrumental in understanding that ALS is a peripheral 




susceptibility for degeneration. They sectioned the gastrocnemius, soleus and tibialis 
muscles to determine the extent of degeneration. Each of these muscles is innervated by 
nerves of similar length in the mouse. The data presented in chapter 5 fills in this gap by 
providing evidence that the longer the axon, the earlier it degenerates. The ability to study 
length-dependent degeneration in peripheral axons is easier to perform in the LTN–CMM 
system as axons of different lengths can be studied within the same muscle preparation. 
This is much easier than having to look at different muscles to generate a large difference 
in axon length. We were also able to record electrophysiological data from three different 
lengths within the same muscle to generate more information about how there is a length-
dependent functional decline. Using the CMM also allows for the entire muscle to be 
stained and whole mounted. By being able to collect all of this information from a single 
muscle, the LTN–CMM system is a much simpler system to study length-dependent 
degeneration.  
Another characteristic that makes the LTN-CMM system so attractive for 
studying axonal regeneration and sprouting is that it is a type II muscle. Motor fibers that 
innervate fast-fatigable, type IIb muscle fibers have a lower capacity for sprouting in 
response to Botulinum A toxin induced sprouting compared to slow twitch, type I fibers 
(88). We were able detect a low level of axonal sprouting from the LTN in WT mice 
following a partial nerve transection. While the sprouting is very limited, the presence of 
a basal capacity for axonal sprouting provides an interesting system to determine whether 
compounds can enhance this sprouting capacity and potentially improve repair outcomes. 
Additionally, the LTN-CMM system could be used to explore whether BACE1 inhibition 




hostile sprouting environment. In SOD1 mice, it has been shown that there is a limited 
amount of intrinsic sprouting in the early stages of the disease. As the disease progresses, 
this capacity for sprouting gets overwhelmed and cannot keep up with the rate of 
degeneration (87). Due to the LTN–CMM system being made up of only sprouting 
resistant, type II motor fibers, we first examined the extent of sprouting in the SOD1 
mouse in order to determine whether this limited sprouting could be detected. While there 
was some evidence of a few sprouts in some of the SOD1 mice, most of these sprouts did 
not seem to be directed toward areas of denervation in particular. If a compound could be 
used to enhance sprouting in the LTN-CMM system, it may be able to improve 
reinnervation in the early stages of the disease and possibly lead to prolonged motor 
function. 
Another reason for using the LTN-CMM system to study disease progression and 
potential therapeutics is that previous studies have shown that each muscle fiber type is 
affected differently, with type IIb being the most susceptible to denervation in the SOD1 
mouse (88, 134, 137, 169). The varying time points of degeneration in the different types 
of motor fibers confound the investigation of the effect of axon length on degeneration, 
as various regions have unique motor fiber type makeups. If one region consists of more 
type IIb fibers, then it may show greater degeneration compared to a longer region 
consisting of more type I fibers. The LTN–CMM system eliminates any possible 
confusion with the different degeneration profiles of different motor fiber types as it only 
consists of type II fibers, which we verified in this study. This eliminates the variable of 
different fiber types and allows for a more consistent study of how the length of the axon 




fatiguing, α-motor axons innervating type II muscle fibers is a length-dependent process 
in the SOD1 mouse model. 
In order to study how axon length affects degeneration susceptibility at the 
earliest stages of disease, we used SOD1G93A mice on the C57BL/6J background. The 
C57BL/6J SOD1 mice show clinical symptoms on average around 110 days and die 
around 150 days (129, 138-141), while those on a mixed background show clinical 
symptoms starting at around 90 days and die by 130 days (86, 131, 132, 135, 138). The 
BL/6J background is advantageous in studying earlier degeneration because the later 
onset of clinical symptoms allows for more time to study the time course of degeneration 
in these long axons. We observed that there is extensive degeneration almost 2 months 
prior to the onset of clinical symptoms in the BL/6J SOD1 mice. The early time point of 
the LTN degeneration is advantageous since it allows for a quicker investigation of 
degeneration of the type II motor synapses well before the onset of symptoms. Also, 
using the LTN–CMM model in the C57BL/6J backgrounds gives a few more weeks of 
studying degeneration before the onset of clinical symptoms and may be a better system 
to study early intervention therapies. 
 
BACE1 inhibitors as a therapy for traumatic peripheral nerve injuries 
 Using the knowledge that too much BACE1 activity levels were detrimental to 
axonal regeneration and genetically knocking out BACE1 led to improved regeneration 
following a nerve crush injury, we explored whether BACE1 inhibitors would be able to 
enhance regeneration as well. After giving WT mice a BACE1 inhibitor, the extent of 




mice that did not receive any treatment. This enhanced regeneration was seen both in the 
number of regenerating axons and extent of NMJ innervation, as well as in the recovery 
rate of the amplitude of the CMAP. We did notice, however, that the recovery of the 
CMAP amplitude was not different between vehicle and inhibitor treated mice halfway 
through the experiment, after 4 weeks of treatment following the injury. What we did 
observe was that the area under the curve of the CMAP traces in the inhibitor treated 
mice was greater than the vehicle treated mice. This was an interesting finding and we 
hypothesize that this difference was due to myelination issues surrounding BACE1 
inhibition. While there may have been more axons firing, because the myelination of 
these axons was impaired, they were unable to fire in a cohesive manner allowing the 
fewer, but better myelinated, vehicle treated axons to fire with a similar amplitude. We 
then removed the inhibitor treatment and recorded the CMAPs again 2 weeks later and 
found that the inhibitor treated mice were now able to fire together and generate a greater 
amplitude. This finding raises a question about how BACE1 inhibitors should be used to 
treat peripheral nerve injuries. While BACE1 inhibition was able to increase the number 
of regenerating axons, functional recovery was impaired, most likely due to myelination 
issues. For optimal recovery, it would be most beneficial to provide patients with BACE1 
inhibitors as soon as possible following injury in order to maximize the effects that 
BACE1 inhibition has on enhancing regeneration and then removing the treatment to 
allow for proper remyelination to occur. Another possibility that needs to be addressed is 
whether these BACE1 inhibitors are also able to increase macrophage influx and debris 
clearance following injury as we saw with an earlier experimental BACE1 inhibitor as 




 In addition to enhancing regeneration of the proximal stump following a nerve 
crush injury, reduced BACE1 activity, by both genetic and pharmacological intervention, 
was able to induce increased terminal axonal sprouting in a partial nerve transection 
injury. This is important because partial nerve transections are a more severe injury due 
to the disconnect between the proximal stump and distal portion of the axon and the 
regenerating axon has difficulty entering the correct tube. By enhancing sprouting at the 
level of the muscle, the muscle has a chance at getting reinnervated earlier than waiting 
for the proximal stump to make it down to the muscle, if it even succeeds. This is also 
important for transections of very long axons as the rate of regeneration is incredible slow 
and collateral sprouting can reinnervate the muscle before any degeneration of the muscle 
occurs due to a lack of neuronal input. We were also able to observe many terminal-to-
terminal sprouts in BACE1 inhibitor treated mice. This implies that these terminal 
sprouts were actually finding denervated NMJs and reinnervating them and not just 
wandering off without reinnervating anything. 
Another important finding was that there weren’t any issues with the morphology 
and functionality of uninjured nerves in mice treated with or without the inhibitor. This 
indicates that reducing BACE1 after the peripheral nerves have had a chance to become 
fully developed doesn’t appear to have the issues with hypomyelination that is seen in the 
complete BACE1 KO mice. Additionally, mice where neuregulin was conditionally 
knocked out in the adult also do not show any issues with the maintenance of myelin in 
uninjured axons (190). This is good for BACE1 inhibitor treatment of peripheral nerve 
injuries as there appears to be no negative effect on normal nerve morphology and would 




Early treatment with BACE1 inhibitors improves CMM innervation in 
an ALS mouse model 
 In addition to determining whether BACE1 inhibitors were useful for enhancing 
peripheral nerve regeneration in traumatic nerve injuries, we also explored whether these 
inhibitors could improve reinnervation of the CMM in the SOD1G93A mouse model of 
ALS. After treating one month old mice with the inhibitor for either one or two months, 
there was an increased percentage of innervated NMJs as well as a functional 
improvement following the one-month inhibitor treatment. After two months of treatment 
there was no longer a significant functional difference despite seeing improved NMJ 
innervation. This may be due to the extent of the disease overwhelming the repair process 
and at that point the neurons themselves may be too sick to fire in any meaningful way. 
Another possibility could be that the size of the motor units has become too large for the 
neurons to be able to support and therefore leads to impaired firing capacity. A third 
possibility could be due to BACE1’s impairment on remyelination and the axons may be 
having difficulty firing together, like what we observed after 4 weeks of treatment 
following a sciatic nerve crush injury. However, just observing the CMAP traces did not 
indicate any substantial difference in the firing cohesiveness nor were there any 
differences in the latencies, ruling this out as a possible reason for the loss of 
significance. 
 In addition to improved NMJ innervation, we were also able to observe an 
increase in the extent of axonal sprouting in these mice following BACE1 inhibitor 
treatment. This is a similar observation as the one that we detected in the partial nerve 




that BACE1 activity levels influence peripheral nerve regeneration by enhancing axonal 
outgrowth, both from the proximal stump and via collateral sprouting from neighboring 
axons. That there was enhanced axonal sprouting evident in the treated SOD1 mice also 
supported the hypothesis that the improved innervation seen with BACE1 inhibition is 
due to enhanced reinnervation and not a neuroprotective effect. This finding indicates 
that BACE1 inhibitors may be beneficial in other neurodegenerative diseases that have a 
peripheral neuropathy, such as CMT or diabetic peripheral neuropathies. This is further 
supported by our finding that BACE1 inhibitors also improve regeneration and sprouting 
in two different traumatic nerve injury models. In addition to the improved innervation 
being caused by enhanced collateral sprouting, we cannot exclude the possibility that 
some regeneration may be due to the retraction bulbs being encouraged to regenerate 
back towards its NMJ as we have not studied this phenomenon. This may be possible as 
we demonstrated that the proximal stump of a nerve crush injury was able to regenerate 
back out following BACE1 inhibitor treatment and a similar mechanism may also be at 
work in the SOD1 mouse. In order to conclude this however, further studies would need 
to be conducted to identify sprouts growing out of retraction bulbs as it is not as easy to 
determine as terminal sprouts. 
 This study provided encouraging findings in terms of using BACE1 inhibitors as a 
way to enhance axonal sprouting in the case of partial peripheral nerve injury due to a 
chronic disease providing the neurons remain sufficiently viable. We were able to 
demonstrate that there is enhanced reinnervation due at least in part to increased 
collateral sprouting in the early stages of the disease. Further studies need to be 




improvements, such as improved grip strength and performance on a rotarod apparatus. 
Additional studies would also need to be conducted to determine whether there is any 
benefit to survival in these mice following BACE1 inhibitor treatment. Another 
interesting future study would be to utilize an ALS mouse model which has a slowly 
progressing disease process as this may be able to further demonstrate the benefits of 
BACE1 inhibitors as there is an even greater window of opportunity for treatment before 
the disease progression overwhelms the repair process. It may also be interesting to 
provide BACE1 inhibitors together with Riluzole and determine whether both treatments 
together can improve the modest effect that Riluzole has on survival for ALS patients.  
 
Final conclusion 
 The studies outlined in this dissertation provided further insight into the 
mechanisms that peripheral nerves are able to control the extent of regeneration. We 
further supported the hypothesis that BACE1 negatively influences peripheral nerve 
regeneration. We were able to demonstrate that BACE1 inhibitors are a promising novel 
treatment not only for acute traumatic peripheral nerve injuries, but also in the context of 
a chronic disease model. These preclinical results hold a lot of promise for the 









Chapter 8: Methods 
Animals 
All experiments and animal care procedures were conducted in accordance with 
the guidelines of the Johns Hopkins University Committee on the Use and Care of 
Animals. Mice associated with this study were housed in a facility at Johns Hopkins 
University. Animal numbers used in each experiment were determined based on previous 
experience (25, 126, 170, 172). For all the experiments performed there was no 
significant difference between male and female mice and therefore the data was pooled 
together according to genotype. 
BACE1 overexpression experiments  
A total of 36 WT and 40 BACE1 transgenic (Tg) mice were used in this study. 
The transgenic mice were graciously provided by Dr. Eliezer Masliah at UCSD. All mice 
were between 3 and 4 months of age at the time of the experiment. The transgenic mice 
were engineered to over-express the human BACE1 protein in neurons (44) and their 
control littermates were designated as wild type.  
BACE1 KO experiments 
A total of 4 WT and 4 BACE1 KO mice were used in this study. All breeding 
mice were obtained from Jackson Labs (Bar Harbor, Maine, USA). Yellow fluorescent 
protein (YFP)-transgenic mice (B6.Cg-Tg(Thy1-YFP)16Jrs/J), in which all the motor 
axons express YFP fluorescence (191), were bred with BACE1 KO mice crossed 10 




Johns Hopkins, to generate KO mice expressing YFP in all their axons. Mice were 3-4 
months old at the time of experiments. 
Injury experiments in WT mice 
 WT type mice on the B6 background were obtained from existing breeding cages 
from our lab. For the inhibitor studies following a sciatic nerve crush, a total of 53 mice 
were used, with 29 on the vehicle and 24 on the inhibitor treatment. For the partial nerve 
transection studies, WT mice expressing YFP on the B6 background from Jackson Labs 
were used (B6.Cg-Tg(Thy1-YFP)16Jrs/J). A total of 10 mice were used, with 3 on the 
vehicle and 4 on the inhibitor treatment. 3 YFP mice were used to determine the 
reliability of a partial nerve transection in the LTN-CMM system. 3 non-YFP B6 mouse 
were used to perform the staining and muscle type characterization experiments of the 
LTN-CMM. 
SOD1 experiments  
All breeding mice were obtained from Jackson Labs (Bar Harbor, Maine, USA). 
Yellow fluorescent protein (YFP)-transgenic mice (B6.Cg-Tg(Thy1-YFP)16Jrs/J), in 
which all the motor axons express YFP fluorescence (191), were bred with SOD1 
transgenic mice (B6.Cg-Tg(SOD1*G93A)1Gur/J) (129), which express a G93A mutant 
form of human SOD1 and exhibit an ALS-like phenotype. Both lines used in this study 
were in the C57BL/6J genetic background. Progeny from breeding pairs were genotyped 
and grouped into SOD1-transgene carrying mice (SOD1) and wild type littermates (WT). 
During the 3-month course of the studies, the SOD1 mice showed no signs of disease, no 




For the degeneration studies, a total of 73 wild type (WT) and 72 SOD1 mice 
were used. Mice were between 1-3 months of age. For the inhibitor studies a total of 142 
SOD1 mice were used, with 69 on vehicle and 73 on inhibitor treatment. Mice were 
between 2-3 months of age at the time of the experiments. Control littermates were 
designated as WT. 
Mouse perfusion 
Before perfusion, LTN or sciatic nerve electrophysiological experiments were 
carried out and when necessary, the hair was removed from the dorsal portion of the 
trunk of the body and legs with electric clippers to prepare for CMM dissection. Mice 
were then deeply anesthetized with 10% chloral hydrate (Sigma–Aldrich, St. Louis, MO, 
USA) and killed by transcardial perfusion with 1 X phosphate-buffered saline (PBS) 
(Life Technologies, Carlsbad, CA, USA) followed by 2% paraformaldehyde (PFA) 
(Electron Microscopy Sciences, Hatfield, PA, USA) in 1 X PBS at room temperature. 2% 
PFA was decided on in order to reduce background fluorescence when imaging. For the 
CMM dissection, the remaining hair was removed from the back of the body with an over 
the counter chemical depilatory. The skin, with the CMM attached, was removed from 
the back of the body and post-fixed in 2% paraformaldehyde for up to 16 h and before 
being transferred to PBS for long term storage at 4 °C. Both injured and uninjured sciatic 
nerves were removed and post-fixed overnight at room temperature for light microscopy 
in 2% PFA and electron microscopy in 2% PFA/2% gluteraldehyde. Both the left and 
right gastrocnemius muscles were removed from the perfused mice and post-fixed in 2% 





Tissue processing for light and electron microscopy  
For semi-thin sections, sciatic nerves were post-fixed at room temperature 
overnight in 2% PFA/2% gluteraldehyde followed by OsO4 and embedded in Epon (all 
from Electron Microscopy Sciences). The nerves were then cross sectioned at a 1 μm 
thickness and stained for toluidine blue before being examined under light microscopy. 
For ultra-structural analyses, nerves were processed as described previously (25). Briefly, 
70 nm thin sections were obtained and stained for citrate/uranyl acetate. Electron 
micrographs were acquired using a Zeiss Libra transmission electron microscope (Zeiss, 
Germany). Sciatic nerves used for early regeneration and degeneration analyses were 
post-fixed overnight at room temperature in 2% PFA in 1 X PBS before being transferred 
to 1 X PBS and stored at 4 °C. Nerves were cyroprotected in 30% sucrose (Thermo 
Fisher Scientific, Waltham, MA, USA) in 1 X PBS overnight before being immersed and 
quick-frozen in Tissue-TEK (Electron Microscopy Sciences), and sectioned 
longitudinally at a 20 μm thickness using a cryostat (Microm HM 505E, International 
Medical Equipment, MI, USA). Sciatic nerves used for the 15 days post crush 
neurofilament study were processed in the same way before being cross-sectioned at a 
20 μm thickness using the same cryostat. Following dissection, gastrocnemius muscles 
were cryoprotected in 30% sucrose in 1 x PBS overnight. The gastrocnemius muscles 
were then frozen using dry ice and 50 µm thick sections were cut using a microtome 
(Microm MH450, Thermo Fisher Scientific). For muscle type analysis samples of the 
CMM from each recording site were collected immediately after recording, flash-frozen 
with liquid nitrogen and stored at −80 °C. Soleus muscles were obtained and prepared in 




Sciences) and cryosectioned at a thickness of 20 μm before both H&E and fiber type 
staining protocols were performed. 
 
Nerve injury protocols 
Sciatic nerve crush 
The mice were anesthetized using 2–3% isoflurane (Isosol, Vedco, MO, USA) 
and the hair on their left thigh was shaved off using an electric clipper. A small incision 
was made along the thigh and the sciatic nerve was exposed. The left sciatic nerve of all 
the mice were crushed at mid-thigh level, just below the sciatic notch, by pinching the 
nerve between tweezers for 30 s before suturing the wound closed. The nerves were then 
monitored electrophysiologically through the progression of regeneration for eight weeks, 
taking measurements every 2 weeks. For the inhibitor studies, mice were taken off the 
drug at 4 weeks to allow optimal remyelination to occur. For morphological analysis, the 
crush sites were marked by 11–0 sutures during surgery and the sciatic nerves were 
removed 3, 10, and 14 days after the crush. Sciatic nerves were collected above and 
below the crush site for the early regeneration marker studies at 3 days. For the 10 and 
14 day regeneration analysis, 2 mm long nerves segments that were 3 mm distal to the 
marked injury site were collected for toluidine blue staining and EM processing. The 
remaining portion of the nerves were saved for neurofilament analysis. 
Sciatic nerve transection 
The mice were anesthetized and prepared as described for sciatic nerve crushes. 
Again, a small incision was made along the thigh to expose the sciatic nerve. The sciatic 




stump to prevent regeneration before suturing the wound closed. The distal stumps were 
collected 5 days later and processed for nerve degeneration analysis. 
Partial LTN transection 
WT and BACE1 KO mice were anesthetized using 2–3% isoflurane and the hair 
was removed from the left shoulder using electric clippers. A small incision was made 
along the shoulder blade and the branches of the LTN were exposed. Two of the branches 
were completely cut and the ends were turned away from each other to prevent the 
proximal stump from reaching the distal portion. The wound was then closed and mice 
were perfused 7, 14 and 21 days later for further analysis of axonal sprouting in the LTN-
CMM. 
 
DRG primary culture 
12 mm coverslips were coated with Poly-L-Lysine (Sigma) for 30 mins at 37°C 
before coating with 10mg/ml laminin (Millipore-Sigma) overnight at 37°C. DRGs were 
isolated from 3 WT mice between 2-4 months of age. To obtain DRGs, mice were 
anesthetized by isoflurane before being decapitated and exposing the spinal column. 
DRGs were collected from the lumbar region on both sides and immediately placed in a 
dish of ice cold L-15 dissection medium. Any extraneous axonal processes were quickly 
removed from the DRGs and then they were mechanically teased apart under a dissection 
scope. 10mg/ml of collagenase (ThermoFisher) was used to further break down the cells 
at 37°C for 45 mins, with mild agitation every 10 mins. The collagenase was then 




(Millipore-Sigma) was added for 15 mins at 37°C. The cells were triturated and then 
strained through a 40µm pore filter before plating at a density of 5x104 cells/well. 
 
Electrophysiology protocols 
Sciatic nerve electrophysiology 
To assess the speed and degree of recovery, we performed electrophysiological 
recordings of the CMAP from crushed nerves every other week for 8 weeks using an 
Evidence 3102evo EMG system (Schreiber & Tholen Medizintechnik, Stade, Germany). 
The recording electrode was placed in the plantar muscle of the foot pad and the sciatic 
nerve was stimulated at two locations. The hip stimulating site was located proximal to 
the injury at the sciatic notch, approximately 30 mm from the recording site. The ankle 
stimulating site was located distal to the injury at the ankle, approximately 10 mm from 
the recording site. A diagram of the electrode placements is shown in Fig. 10A. The 
recordings were performed in an anesthetized mouse using isoflurane and the crushed 
sciatic nerve was stimulated at the hip or ankle by very short (< 0.2 milliseconds) 
electrical impulses. The skeletal muscle in the foot pad innervated by this nerve generated 
a CMAP after regenerated axons re-innervated the muscle. The amplitude level and 
latency of the response at the muscle were analyzed as readouts for the degree of 
functional recovery. The traces of the CMAPs in Figs. 10B-C, 16C and 22A-D were 
generated by exporting the values from the Evidence software into SigmaPlot (Systat 
Software Inc., CA, USA) to create a line graph representing the CMAP traces. Uncrushed 






Mice were anesthetized using 2–3% isoflurane and the hair on their backs was 
removed by shaving with electric clippers. CMAPs were recorded from the LTN–CMM 
at three sites along the CMM using an Evidence 3102evo EMG system. In order to 
accurately determine each testing site, an easily identifiable baseline site between the 
second and third caudal vertebrae was established by palpating for the muscle mass on 
top of the third caudal vertebrae. Testing sites were marked 6, 24, and 36 mm anterior to 
the baseline site, with the recording and reference electrodes placed 6 mm on either side 
of the animal’s midline. Two small incisions were made at the most caudal testing site 
and both the active and reference recording electrodes were placed just beneath the skin. 
A diagram of the experimental set up is shown in Fig. 13A. The grounding electrode was 
placed beneath the skin on the animal’s side away from the recording and stimulating 
electrodes. An incision was made just below the left shoulder blade and the LTN was 
exposed proximal to where the nerve enters the CMM. Using a hooked electrode, the 
middle branch of LTN was isolated and stimulated (0.05 ms, 1 Hz). Stimulation was 
optimized with respect to both polarity (preferred polarity yielding the shortest CMAP 
latency) and intensity (supramax stimulation defined as 3 mA above the amount of 
current required for the size and shape of the CMAP to remain unchanged). CMAPs from 
the LTN–CMM system were then recorded and amplitudes and latencies were analyzed 
as measures of neuromuscular function. Repetitive stimulation schedules (optimized 
stimulation at 1, 5, and 10 Hz) were used to ensure stable electrode positioning. After 
testing was completed at the caudal site, the active and reference recording electrodes 




head at the medial and then the rostral testing sites. The traces of the CMAPs in Figs. 
13A and 24D were generated by exporting the values from the Evidence software into 
SigmaPlot to create a line graph representing the CMAP traces. 
 
Tissue staining 
Table 1. Antibodies used for tissue staining.  
1° Antibody Target Company Dilution 
Neurofilament H (NF) Axonal marker Millipore 1:500 
Synaptic vesicle 2 (SV2) Presynaptic terminal DSHB 1:250 
Myelin basic protein 
(MBP) 
Myelin sheath Millipore 1:1000 
CD68 Macrophages Serotec 1:1000 
GAP-43 Early regeneration marker Millipore 1:1000 
SCG10 Early regeneration marker Novus 1:2000 
α-bungarotoxin-AF647 
conjugate 
Postsynaptic NMJ Life Technologies 1:500 
S-100 Schwann cells Sigma-Aldrich 1:250 
Type I myosin heavy chain 
(A4.840) 
Type I muscle cells DSHB 1:250 
Type II myosin heavy 
chain (My32) 
Type II muscle cells Thermo Fisher 1:500 
Neurofilament 200 Axonal marker Sigma 1:500 
Tuj1 Neuronal marker Covance 1:1000 
 
Cultured DRG neurons 
 Cultured DRGs on glass coverslips were fixed for 1 hour with 2% PFA in 1 X 
PBS at room temperature. Cells were then washed in PBS before being permeabilized 
and blocked by 5% goat serum (Jackson labs)/0.3% Triton (Sigma-Aldrich) in 1 X PBS 
for 1h at room temperature. The cells were then stained with either a Tuj1 or NF-200 




then stained with appropriate secondary antibodies conjugated to AlexaFluor 488 before 
being mounted on slides in ProLong Gold mounting medium with DAPI (Life 
Technologies). 
Sciatic nerve staining 
Sciatic nerve sections affixed to slides were permeabilized and blocked by 5% 
goat serum (Jackson labs)/0.3% Triton (Sigma-Aldrich) in 1 X PBS for 1h at room 
temperature. The cross-sections were stained with a primary antibody against NF and the 
longitudinal sections stained with an anti-GAP43, anti-SCG10, anti-MBP, or anti-CD68 
antibody at 4C overnight. The samples were then washed in PBS for 5 minutes 3 times 
before the appropriate Alexa Fluor conjugated secondary antibody was added for 1 hour 
at room temperature. The samples were again washed and then mounted in prolong gold 
mounting reagent with DAPI (Life Technologies) and cover-slipped. 
Gastrocnemius muscle staining 
Free floating gastrocnemius muscle tissue sections were permeabilized and 
blocked by 5% goat serum (Jackson labs)/0.3% Triton (Sigma-Aldrich) in 1 X PBS for 
1h at room temperature. The sections were stained with primary antibodies against NF H 
and SV2 at 4C overnight. The samples were then washed in PBS for 5 minutes 3 times 
before appropriate Alexa Flour conjugated secondary antibodies were added together 
with -BTX Alexa Fluor 647 for 1 hour at room temperature. The samples were again 








LTN-CMMs were collected for analysis for the partial nerve transection studies in 
BACE1 KO mice and inhibitor treated WT mice as well as for the SOD1 degeneration 
and regeneration studies. Before staining, the connective tissue covering the CMM was 
carefully dissected off of the whole back while leaving the skin intact. The back was then 
cut in half along the midline and one side from the SOD1 mice was randomly selected for 
staining. For the partial nerve transection studies the left side of the back was selected. 
The muscle was permeabilized for 1 h at room temperature in a solution of 1% Triton X 
and 5% dimethyl sulfoxide (DMSO) (Sigma–Aldrich) in 1× PBS. They were then stained 
with α-bungarotoxin conjugated to Alexa Fluor 647 (Life Technologies) at room 
temperature for 3 h. The back halves were then whole mounted onto slides using 
ProLong Diamond Antifade mounting medium (Life Technologies). CMM tissue from 
WT mice were also blocked in the same permeabilization solution with 5% goat serum 
(Jackson ImmunoResearch Laboratories Inc., West Grove, PA, USA). I blocked the 
tissue with Mouse on Mouse blocking reagent then stained the whole CMM from WT 
mice for SV2 and Schwann cells (S-100) to identify endogenously expressed markers of 
the neuromuscular synapse. 
Muscle type staining 
Dissected CMMs were washed and a standard H&E staining protocol was 
followed (Thermo Fisher, Halethorpe, MD, USA). For fiber typing, samples were 
permeabilized in a solution of 0.3% Triton X (Sigma–Aldrich) in 1× PBS, blocked with a 




labeled with antibodies to identify type I myosin heavy chain (A4.840) and type II 
myosin heavy chain (My32). 
 
Regeneration analysis 
Sciatic nerve regeneration 
In order to count all of the regenerated axons, 63X oil-immersion bright field 
images of toluidine blue stained sciatic nerve cross-sections were tiled to obtain the 
complete area of the nerves using as Axio Imager fluorescence microscope (Zeiss, 
Germany). Axons which had evidence of very thin myelin sheaths were scored as a 
regenerated axon and the total number of regenerated axons was scored for the entire 
nerve. Each mouse was assigned a random number and the genotype or treatment status 
of each mouse was unknown at the time of quantification. The results were then 
unblinded and statistical analysis was performed before calculating the average and SEM. 
Early regeneration analysis 
After staining longitudinal sections of 3 days post crush sciatic nerves for GAP43, 
the entire length of the nerves were imaged using a Zeiss LSM 800 confocal microscope 
by tiling 20X images together. The crush site was identified by staining for CD68 
positive macrophages which congregate at the site of injury by 3 days (data not shown). 
The length of the longest GAP43 positive axon was quantified by tracing the nerve in 
Image J software (NIH) from the middle of the crush site to the end and then the length of 
the line was measured. Each mouse was assigned a random number and the genotype was 
unknown at the time of quantification. The results were then unblinded and each 





20 µm longitudinal sections of sciatic nerves stained for CD68, a macrophage 
marker, were used for macrophage quantification. The nerves were imaged using a Zeiss 
LSM 800 confocal microscope at a magnification of 20X to generate 3D z-stacks. The 
number of CD68 positive macrophages were counted and the macrophage density was 
then determined by taking into account the total volume of the image. Each mouse was 
assigned a random number and the genotype was unknown at the time of quantification. 
The samples were then unblinded and statistical analysis was performed before 
calculating the average and SEM. 
NMJ reinnervation 
LTN–CMM imaging was done by imaging whole-mounted back halves with a 
20X objective using an Axio Imager fluorescence microscope with an Apotome 
apparatus (Zeiss) and two laser scanning confocal microscopes (LSM 510 and LSM 800, 
Zeiss). The backs were imaged at three different locations along the CMM corresponding 
to the caudal, medial and rostral regions used for the electrophysiological experiments (6, 
24, and 36 mm from the baseline respectively). Stained and mounted gastrocnemius 
muscle sections were imaged at 20X on a LSM 800 Zeiss microscope. Z-stacks were 
taken for each image and were flattened with the ZEN software (Zeiss). The gamma and 
brightness was raised on the images in order to visualize axons with low YFP expression. 
Approximately 100-150 NMJs were imaged at each CMM site and gastrocnemius per 
mouse. To determine the extent of innervation, NMJs were counted and scored as either 
completely innervated or fully denervated. Complete innervation was counted as a total 




denervated NMJs were counted as no overlapping of the pre-synaptic and post-synaptic 
staining. The number of innervated NMJs was then divided by the total number of NMJs 
to determine the percentage of innervation. Each mouse was assigned a random number 
and the genotype was unknown at the time of quantification. The samples were then 
unblinded and statistical analysis was performed before calculating the average and SEM.  
Axonal sprouting  
Axonal sprouting in the SOD1 models was analyzed using the same images from 
the NMJ innervation analysis. For the partial nerve injury, images were taken in regions 
adjacent to areas of denervation. I scored thin, YFP-positive axons which innervated a 
NMJ that already had another axon innervating it as an axonal sprout. Extra-terminal 
axonal sprouts were specifically characterized as a thin axon sprouting from a terminal 
bouton that either did or did not make a connection with another NMJ. To calculate the 
percentage of terminal axonal sprouts I counted the number of extra-terminal sprouts and 
divided by the total number of NMJs. 
 
Western Blot 
Fresh, unfixed sciatic nerves and brains were collected from mice and the protein 
was extracted by homogenizing in a glass-made micro-homogenizer in extraction buffer 
(T-PER® tissue protein extraction reagent, Thermo Fisher Scientific, MA, USA) 
containing a protease inhibitor mixture. Protein concentration was determined using a 
Micro BCA™ Protein Assay Kit as per the manufacturer's instructions (Thermo Fisher 
Scientific). Protein was loaded onto a Novex WedgeWell 8–16% Tris-Glycine gel or a 4-




membrane (Invitrogen). The blots were then blocked with 5% milk (Bio-Rad, CA) or 5% 
donkey serum (Millipore) and stained overnight at 4 °C with an anti-BACE1 (39), anti-
APP (Millipore), or anti-CHL1 (R&D Systems, Minneapolis MN) primary antibody. The 
blots were then washed 3 times for 5 minutes in TBST before adding appropriate HRP 
conjugated secondary antibodies for 1 h at room temperature. The blots were washed 
again and then visualized on film using Amersham ECL detection reagent (GE 
Healthcare, UK). The blots were stripped and re-stained for loading controls using an 
anti-GAPDH-HRP conjugated antibody (Sigma-Aldrich) for 1 h at room temperature 
before being visualized in the same way as the other antibodies. 
 
Statistical analysis 
Each mouse was randomly assigned a number and the specific genotype of each mouse 
was unknown at the time of data collection and analysis for all experiments performed in 
order to ensure blinded analysis. Power analyses were performed, together with previous 
experience, to determine sample sizes. All statistical analyses were performed using a 
Student's t-test. Where the data failed to pass the normalization test, the Mann-Whitney 
Rank Sum Test was performed. All data analysis was performed using SigmaPlot 
software and any value of p < 0.05 was scored as statistically significant. All graphed 
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PhD candidate from Johns Hopkins University expected to graduate in December 2017 studying peripheral 
nerve regeneration in injury and disease models via molecular, morphological and physiological analysis. 
Very skilled in nerve surgeries and electrophysiological recordings in mouse models. Expertise using both 
cell and organotypic slice cultures. Tested drug efficacy both in vitro and in vivo models. Mentored and 
managed junior lab members in various experimental procedures. Skilled at effectively presenting oral and 
written scientific information to a variety of audiences. Highly interested in identifying novel drug efficacy 
in neurodegenerative diseases. 
 
EDUCATION 
PhD Candidate in Pathobiology                     August 2013 – December 2017 
Johns Hopkins School of Medicine, Baltimore, MD, USA 
PhD Thesis: BACE1 activity levels inversely influence peripheral axon regeneration. 
Thesis mentor: Dr. Mohamed H. Farah 
 Determined that BACE1 activity levels inversely influence axonal repair in acute peripheral nerve injury 
mouse models. 
 Tested the efficacy of BACE1 inhibitors on enhancing regeneration in acute peripheral nerve injury and 
neurodegenerative mouse models. 
Bachelor of Science in Physiology                                                                                May 2013 
First class honours with distinction, McGill University, Montreal, QC, Canada 
Undergraduate Honours Thesis: Attenuated vestibular-only neurons show greater spike train variability 
during active motion. 
Thesis mentor: Dr. Kathleen Cullen 
 Explored whether attenuated vestibular-only neurons altered their firing rate variability between self-
generated and externally generated head motion. 
 
ADDITIONAL RESEARCH EXPERIENCE  
Summer Research Assistant                          May 2013 – August 2013 
Dr. Claire Brown - McGill Imaging Facility, McGill University, Montreal, QC 
 Imaged live ErbB2 breast cancer cells to determine whether TGF- modulates cell motility 
Summer Undergraduate Research Assistant                      May 2011 - August 2011 
Dr. Karine Auclair - Chemistry Department, McGill University, Montreal, QC 
 Tested novel bisubsrate inhibitors on aminoglycoside resistance enzymes to determine whether the 
inhibitors were specific to acetyltransferases 
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Microscope Use Trainer - Advanced Bioimaging Facility, McGill University  October 2012 - May 2013 
 Learned how to operate conventional and confocal microscopy to assist novel users 
 
VOLUNTEER WORK 
Sabin Pathology Club - Johns Hopkins School of Medicine            October 2016 – present 
 Prepared and presented biannual hour long lectures on the physiology and pathology of various 
biological systems of the human body and participated in lively scientific discussions 
Pathobiology Social Committee - Johns Hopkins School of Medicine                July 2014 – June 2015  
 Effectively led committee by delegating tasks to efficiently organize events for pathobiology students 
Graduate Student Association - Johns Hopkins School of Medicine                  June 2014 – June 2015 
 Managed various GSA list serves and created weekly newsletters detailing events for graduate students 
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 Grant Writing – Presented training plan and grant critique sessions, edited student grants 
 Neuropathology – Organized lecture notes and exam answers, assisted with scheduling 
 Basic Mechanisms of Disease – Presented lecture on bone and muscle physiology and pathology 
Chief Pathobiology Graduate Student - Johns Hopkins School of Medicine         July 2015 – June 2016 
 Elected to the position by the chief of pathology, Dr. Ralph Hruban  
 Effectively solved student issues and communicated them to the pathobiology executive board 
 Helped organize pathobiology events including orientation, retreat, and recruitment 
 Successfully mentored first year students through classes and second year students through doctoral 
board oral exams 
 Coordinated and scheduled the pathobiology journal club and Wednesday lunch meetings 
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improves nerve regeneration in axonal injury and disease models. In preparation. 
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terminal degeneration at the neuromuscular synapses of type II muscle in SOD1 mice. Neurosci 312: 179-
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PRESENTATIONS AND POSTERS 
 “Terminal axonal sprouting is augmented in partially injured motor nerves of BACE1 KO mice” 
Nanosymposium talk - 2016 Society for Neuroscience Conference. Nov 2016. 
 “Reduced BACE1 Activity Enhances Neuromuscular Junction Innervation in SOD1 and Axonal Injury 
Mouse Models” Flash talk and poster presentation - 2nd Kloster Seeon Meeting on BACE Proteases in 
Health and Disease. Sept 2016. 
 “Inhibition of BACE1 in the SOD1G93A mouse model of ALS enhances neuromuscular junction 
remodeling” Nanosymposium talk - 2015 Society for Neuroscience Conference. Oct 2015. 
 “Reducing BACE1 activity via pharmacological and genetic intervention improves neuromuscular 
junction remodeling in both ALS and partial motor axon injury models” Research talk and poster 
presentation - 3rd Ottawa International Conference on Neuromuscular Biology, Disease and Therapy. 
Sept 2015. 
 “Enhancing the plasticity and remodeling of neuromuscular junctions in a motor neuron disease mouse 
model by inhibiting BACE1” Generated poster – MDA Scientific conference. Mar 2015. 
 
AWARDS & HONOURS 
 Golden microscope award for best senior research talk – 2017 Pathobiology Retreat        2017 
 Travel award - 2nd Kloster Seeon Meeting on BACE Proteases in Health and Disease        2016 
 Best 2nd year poster at the JHU annual pathobiology program retreat                    2014 
 NSERC Undergraduate Student Research Award                     2013 
 Science Undergraduate Research Award                      2011 
 Michael and Lina Chan Scholarship in Science                     2010 
 Dean’s Honour List                 2010 
 A S Hill Scholarship for academic excellence                      2009 
 
CERTIFICATIONS 
 CPR (2017), Electronic Information Security and Data Management Training (2017), Research Ethics I 








 English (native), French (basic skills) 
 
SKILLS 
 Mouse surgery and electrophysiology 
 Muscle dissection, fixation, and sectioning 
 Immunofluorescence 
 Microscopy (confocal, brightfield, apotome, EM) 
 Molecular biology (PCR, ELISA, Western Blot, Protein concentration assays, Enzymatic activity) 
 Organotypic spinal cord slice culture 
 Primary cell culture and human iPSCs 
 Basic MATLAB and java coding 
 Scientific writing and presenting 
 Lab management and personnel mentoring 
 
MEMBERSHIPS 
Golden Key McGill Chapter, Society for Neuroscience 
